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1 Introduction 
Asthma and chronic obstructive pulmonary disease (COPD) are two diseases 
characterized by airflow limitation due to either reduced driving pressure (loss of 
elastic recoil of the lung parenchyma) or an increased resistance (airway 
obstruction) which is mostly reversible in asthma and mostly irreversible in COPD 
(1, 2). Airway remodeling is a pathological feature observed both in asthma and 
COPD. The most important difference between asthma and COPD is the nature 
of inflammation, which is primarily eosinophilic and CD-4 driven in asthma, and 
neutrophilic and CD-8 driven in COPD (3). In spite of these differences fibrotic 
alterations are observed in both these diseases (4). Cholinergic pathway 
represents key mechanisms in control of airway smooth muscle tone. 
Anticholinergic bronchodilaters reduce vagal cholinergic tone, the main reversible 
component in COPD hence constitute an essential element in the therapy of 
obstructive airways diseases especially in COPD (5, 6). Furthermore tiotropium 
bromide (Spiriva®) a long acting muscarinic antagonist was found to delay the 
decline in airway function in COPD (7, 8, 9), suggesting that cholinergic 
mechanisms plays a pivotal role in the structural changes associated with airway 
remodeling. In studies carried out on human and bovine airway smooth muscle it 
was seen that muscarinic agonists enhanced the proliferative response to 
epidermal growth factor and platelet-dervied growth factor respectively (10, 11). 
Moreover, tiotropium was found to attenuate the increase in airway smooth 
muscle mass and myosin expression induced by repeated allergen challenges 
(12). Almost every cell type in the airways expresses cholinoreceptor (13, 14) 
and hence could be a target for acetylcholine released from neuronal or 
nonneuronal sources (13, 15). Expression of mRNA encoding different nicotinic 
receptor subunits (16) and M2 receptors in airway fibroblasts has been described, 
but a detailed study on expression of muscarinic receptor subtypes in lung and 
airway fibroblasts is still lacking. It has been shown that the activation of nicotinic 
receptors stimulates collagen gene expression and fibronectin synthesis (17, 18) 
whereas the functional role of muscarinic receptors in airway fibroblasts remains 
to be illuminated.  
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The purpose of this study was to determine the expression pattern of the 
muscarinic receptors in human lung fibroblasts and to investigate whether 
muscarinic receptors mediate effects on cell proliferation and if so, to elucidate 
the intracellular signaling pathways entailed. 
 
1.1 Neuronal and Non-Neuronal Acetylcholine 
ACh represents the ‘classical’ neurotransmitter of the parasympathetic nervous 
system. As neurotransmitter ACh is synthesized in the nerve endings by the 
enzyme choline acetyltransferase using acetyl-CoA and choline as substrates. It 
is then stored in the synaptic vesicles. Eventually, depolarization-induced calcium 
influx lead to an exocytotic release of the neurotransmitter into the extracellular 
space where it may interact with receptors located on the target cells as well as 
on the cholinergic nerve terminals themselves (13). In order to limit effector cell 
activation, after release, ACh is degraded by acetylcholineesterase to non-active 
choline (19). 
Recent studies have revealed that choline acetyltransferase and its product ACh 
are present in a wide range of non-neuronal cells, including epithelial and 
endothelial cells, smooth muscle cells as well as various cells of the immune 
system such as lymphoctyes, macrophages, eosinophils and neutrophils (20). In 
addition nicotinic and muscarinic receptors have been shown to be widely 
expressed on these non-neuronal cells (21, 22, 23, 24). The essential 
components of the cholinergic system are present, to a greater or lesser extent, 
in many of these non-neuronal inflammatory cells involved in airway physiology 
and pathophysiology. However unlike neuronal cells, where ACh is stored in 
discrete neurosecretory vesicles, cells of the non-neuronal cholinergic system 
appear to release acetylcholine directly upon synthesis via active transport 
mediated by members of the organic cation transporter (OCT) family. Although 
not much is know about the functional role of non-neuronal ACh it has been 
shown to act as a local cell molecule via paracrine and autocrine mechanisms to 
control basic cell functions such as proliferation, differentiation, maturation, 
migration, secretion, organization of the cytoskeleton and cell-cell contact (23, 
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24, 25, 26, 27). In a recent study it was shown that the dysfunction of the non-
neuronal cholinergic system in the airways could contribute to the deleterious 
changes of epithelial ion and water movement involved in the pathogenesis of 
cystic fibrosis a hereditary disease that affects mainly the lungs and digestive 
system, causing progressive disability (28).  
 
1.2 Cholinoceptors 
1.2.1 Nicotinic Receptors 
The nicotinic acetylcholine receptors are pentamers of homologous or identical 
subunits, symmetrically arranged to form a transmembrane cation channel (29). 
There are multiple nicotinic receptor isotypes existing. Muscle nicotinic receptors, 
localized at the end plate of the neuromuscular junctions, are assembled of two 
α-, one β-, one γ- or one ε- and one δ (30), whereas neuronal nicotinic receptors 
appear to be composed either of only two different types of subunits (α and β) or 
of five α- subunits. The activation of the nicotinic receptor causes a net influx of 
positively charged ions resulting in membrane depolarization, which can be 
detected for example as ‘excitatory postsynaptic potential’ at postganglionic 
neurons (13). At least 10 different α- and four β- subunits have been identified so 
far. In addition to the expression of neuronal nicotinic receptor subunits in 
autonomic ganglia, it was observed in almost every other cell type in the airways 
and lung tissues. The α-7 subunit was detected in many non-neuronal cells such 
as the bronchial epithelial cells, endothelial airway cells and airway fibroblasts 
(16). In vitro studies carried out on bronchial epithelial cells and pulmonary 
neuroendocrine cells indicated nicotinic receptor mediated activation of cell 
proliferation cascade (31, 32). It’s worth mentioning that nicotinic receptors in 
non-neuronal cells have also been suggested to be involved in tobacco induced 
toxicity in the airways (33). Furthermore, chronic exposure of murine and human 
bronchial epithelial cells to nicotine both in vitro and in vivo caused an 
upregulation of α-7 and α-3 subunits (34, 35). In another study carried out on 
WI38 cells, a human embryonic pulmonary fibroblast cell line expressing α-3 and 
α-7 nicotinic receptor subunits, nicotine exposure disrupted the specific epithelial-
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mesenchymal paracrine signaling pathways and resulted in pulmonary interstitial 
lipofibroblast (LIF)-to-myofibroblast (MYF) transdifferentiation, which could result 
in altered pulmonary development and function (36).  
 
1.2.2 Muscarinic Receptors 
The muscarinic ACh receptors (mAChRs) are members of the superfamily of 
hormones and neurotransmitter receptors. The muscarinic acetylcholine receptor 
is a seven transmembrane domain receptor that is coupled to a guanosine 
triphosphate (GTP) binding protein (G-protein). The muscarinic receptors 
regulate the activities of intracellular secondary messenger pathways through ion 
channel and enzyme activation/deactivation by interaction with their coupled G-
proteins. Five different subtypes of muscarinic receptors have been identified by 
molecular biological techniques (m1-m5) (37, 38, 39), but so far a sufficient 
pharmacological and functional characterization has been provided for only four 
of them (M1-M4). Nonetheless, there is now significant evidence that the gene 
product of the m5 gene forms a functional muscarinic receptor (M5) (39). The ‘odd 
numbered’ (M1/M3/M5) muscarinic receptor subtypes couple preferentially to the 
pertussis toxin (PTX) insensitive G-proteins of the Gq family, while the ‘even 
numbered (M2/M4) muscarinic receptors bind with G-proteins belonging to the Gi/o 
family. The former subtypes activates phospholipase C (PLC), phospholipase A2 
(PLA2), phospholipase D (PLD), tyrosine kinase and calcium influx but do not 
inhibit adenylyl cyclase, while the latter group of receptors inhibit adenylyl 
cyclase but do not stimulate PLC. However this coupling specificity of the 
mAChRs subtypes is not absolute, for the M2 and the M4 subtypes can weakly 
activate PLC when expressed at high levels in certain cell types (40, 41, 42). The 
PTX-insensitive coupling to PLC is mediated by Gαq, Gα11, Gα14, and Gα16 , while 
the PTX-sensitive coupling to adenylyl cyclase inhibition is mediated by Gαi or 
Gαo (43, 44). 
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1.3 Molecular and Pharmacological Classification of Muscarinic Receptor 
Subtypes: 
1.3.1 Molecular Biology of Muscarinic Receptors 
Subsequent to early pharmacological findings, molecular cloning studies 
revealed five different subtypes of muscarinic receptors (m1-m5) (37). Numa and 
colleagues cloned the m1 and the m2 genes (45, 46). The m3, m4, and m5 gene 
were thereafter discovered (47, 48, 49). The vertebrate cloned receptor genes 
are intronless, and similar across mammalian species (50, 51). These five genes 
encode mAChR glycoproteins that display the structural features of the seven 
transmembrane helix G-protein-coupled receptor family. Based on the 
pharmacological binding studies of each receptor resembling the cloned genes, it 
is now recommended that M1, M2, M3, M4 and M5 be used to describe both 
pharmacological subtypes and molecular subtypes encoded by the cloned 
genes.    
Similar to most members of the G-protein-coupled receptor family whose ligand 
recognition site binds small molecules, there are several major features of 
muscarinic receptor structure. First, the ligand recognition site can be located 
within the outer half of the membrane-embedded part of the protein. To bind the 
neurotransmitter ACh, all muscarinic receptors have an Asp residue in the distal 
N-terminal part of the third transmembrane domain which is thought to interact 
with the polar head of the neurotransmitter and other amine ligands (52, 53). 
Second, the transmembrane segments are α-helical, whereby three helices are 
oriented approximately perpendicular to the membrane, and four helices are 
oriented at a more acute angle (54). Furthermore, there are two conserved 
cysteine residues that form a disulphide bond between the first and the third 
extracellular loops (55, 56). There exists a conserved triplet of amino acids (Asp, 
Arg, Tyr) at the cytoplasmic interface of TMIII with the second intracellular loop 
that is crucial for both the expression and function of the receptor (57, 58, 59). 
Moreover the carboxy terminus of the mAChR is located on the intracellular side 
of the membrane, while the amino terminus is located on the extracellular side of 
the membrane containing one or more glycosylation sites. On the other hand, the 
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fourth intracellular region plus regions near transmembrane area in the second 
and the third internal loops seem to be targeted for phosphorylation by ligand 
stimulated negative feedback loop mediated mAChR kinase (60). Yet, to 
distinguish between the different mAChR subtypes, a sequence divergence in 
the postulated third internal loop (i3) exists between the M1/M3/M5 sequences 
compared with the M2/M4 sequences (38, 61, 62). The sequence divergence 
probably specifies the different coupling preferences of the two categorized 
groups of subtypes. In addition the sequence within the i3 loop differ sufficiently 
between each mAChR subtype that allows raising subtype specific antisera (63)  
 
1.3.2 Pharmacological Classification of Muscarinic Receptor Subtypes 
The task of pharmacologically characterizing mAChR subtypes has been a 
difficult process, especially with the initial lack of agonists with any selectivity in 
addition to the lack of any antagonist with high selectivity for any single receptor 
subtype. Studies were focused on discovering natural agonists or antagonist plus 
attempts to synthesize agonists or antagonists that can bind selectively to each 
subtype to distinguish between each of the five mAChRs. Yet the sites for Ach 
and other agonists were found to be similar among all five mAChR subtypes. 
This was further complicated by the presence of multiple muscarinic binding sites 
in most tissues which emphasized the need of the concept for high selective 
agonist and antagonist that are needed to be used in clinical application for 
disorders resulting from muscarinic abberations. 
The definition of antagonist affinities for the five muscarinic receptors has been 
aided greatly by the use of radioligand binding techniques, with ligands such as 
(3H)pirenzepine and (3H)N-methylscopolamine, in combination with membrane 
preparations from cells transfected with the gene for a particular receptor, and 
thereby expressing a single receptor subtype. Binding studies using two new 
antagonists, hexahydro-sila-difenidiol (HHSiD) and its para-fluoro analogue (p-F-
HHSiD), enabled researchers to distinguish between M2 muscarinic binding sites 
in the heart and the glandular tissues (39). The heart M2 receptor had a 70-fold 
lower affinity for p-F-HHSiD than for the ‘M2’ glandular tissue receptor, which was 
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then found to be distinct from the M2 subtype, and renamed M3 mAChR. Recently 
two new highly selective M2 anatgonists that displays high selectivity between M1 
and M4 subtypes has been developed (64). 
Further studies have lead to more selective antagonist being synthesized 
including the M2 preferential antagonist methoctramine, the M3 antagonist 4-
DAMP and its irreversible analogue 4-DAMP-mustard (65, 66, 67, 68). In addition 
two new snake toxins MT3 and MT7 which show high selectivity for muscarinic 
subtypes M4 and M1 respectively have been discovered (39). In another 
antagonist binding profile study done using a transformed Chinese hamster ovary 
cell line (CHO-K1) individually expressing the various muscarinic receptors it was 
observed that the ‘M3-selective’ agent p-F-HHSiD (69, 70) showed similar 
affinities for M1, M3 and M4 receptors, which were up to 9-fold higher than those 
found for M2 and M5 receptors. All five M2-selective muscarinic antagonists 
employed in the study (methoctramine, himbacine, AF-DX 384, AQ-RA 741 and 
AF-DX 250) bound with high affinities to both M2 and M4 receptors and 
intermediate affinities for M1 and M3 receptors, with the exception of himbacine 
which showed about a 10-fold higher affinity for M2/M4 than for M1 receptor (71).  
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Antagonist affinity constants (log affinity constants or pKB values) for mammalian 
muscarinic receptors. Various selective muscarinic acetylcholine receptor antagonists are 
shown including their pKB values. Data are from a variety of mammalian species, including 
human. Values are adapted from Caulfield and Bridsall (1998). 
Antagonist M1 M2 M3 M4 M5 
Atropine 9.0-9.7 9.0-9.3 8.9-9.8 9.1-9.6 8.9-9.7 
Pirenzepine 7.8-8.5 6.3-6.7 6.7-7.1 7.1-8.1 6.2-7.1 
Methoctramine 7.1-7.8 7.8-8.3 6.3-6.9 7.4-8.1 6.9-7.2 
4-DAMP 8.6-9.2 7.8-8.4 8.9-9.3 8.4-9.4 8.9-9.0 
Himbacine 7.0-7.2 8.0-8.3 6.9-7.4 8.0-8.8 6.1-6.3 
AF-DX 384 7.3-7.5 8.2-9.0 7.2-7.8 8.0-8.7 6.3 
MT3 7.1 <6 <6 8.7 <6 
MT7 9.8 <6 <6 <6 <6 
 
1.4 Muscarinic Coupling to G-proteins and Effector Molecules 
Similar to most seven transmembrane receptors, the mAChRs are coupled to G-
proteins that can transduce the exterior signal in this case the binding of Ach to 
the mAChR and the receptor’s subsequent activation, into an intracellular signal 
governed by specific second messenger cascade that cause many cellular 
responses. The link between the receptors and the effectors is in many cases 
mediated by the heterotrimeric G-proteins. G-protein transduced cellular 
responses include biochemical activities, metabolic changes, enzyme 
activation/deactivation, downstream gene transcription, protein synthesis, cell 
division and cell motility. The heterotrimeric G-proteins are composed of one α-, 
β- and γ- subunits each and are classified on the basis of their α-subunits. More 
than twenty different α-, five β- and ten γ-subunits have been identified at 
present, but based on primary sequence homology of the five α-subunits. G-
proteins have been subdivided into four families: Gαs, Gαi/o, Gαq, and Gα12 (72, 
73). G-proteins shift between their active and inactive state by binding to GTP or 
GDP nucleotide. When bound to the GTP nucleotide, G-protein is in its active 
stable state where it can activate directly diverse effector molecules. The G-
proteins possess an intrinsic GTPase function in the α-subunit which hydrolyses 
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GTP to GDP, and thus induces the GDP binding inactive form. At this inactive 
stage the α-subunit associates with the βγ-subunit. The stimulation of the 
muscarinic recepotor induces the exchange of the GDP to GTP at the α-subunit. 
The binding of GTP results in the dissociation of the α-subunit and the βγ-
complex, as a result both subunits can activate their own specific signals and 
events. Most cellular effects which have been described to be elicited by 
muscarinic receptors involve the α-subunit and the different α-subunits of the G-
proteins are known to mediate distinct cellular signaling by coupling differentially 
with the different muscarinic receptors. The odd numbered muscarinic receptor 
subtypes, M1/M3/M5, are coupled to the PTX-insensitive Gαq protein, while the 
even numbered subtypes of muscarinic receptors M2/M4 coupled to the PTX-
sensitive Gαi/o protein (Figure I). Recently many βγ-subunits have been identified 
playing a functional role in the transduction of muscarinic signals eliciting more 
investigations in their structure and functions (74). The agonist-induced receptor 
phosphorylation by G-protein receptor kinases (75, 76) by this controlling of the 
functional state of the receptors, targeting of ion channels, phospholipase Cβ , 
some isoforms of adenylyl cyclase or phosphoinositide-3-kinase and through this 
the MAP kinase cascade have been attributed to the functional βγ-subunit of the 
G-proteins.  
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Figure I Schematic representation of signal transduction via G-protein coupled receptors 
in smooth muscle cells. M1, M2 and M3 muscarinic receptors, PLC phospholipase C, DAG 
diacylglycerol, IP3 inositol 1,4,5-triphosphate.( adapted after revision from Eglen RM et al 1994)  
 
 
1.4.1 Adenylyl Cyclase 
The decrease in the adenylyl cyclase activity induced by muscarinic receptor 
activation has been well documented (44). The expression of the M2 and M4 
receptors in cell lines displayed coupling to adenylyl cyclase inhibition (44, 64, 
77, 78, 79, 80). In addition, G-protein reconstitution experiments showed that the 
Gi subtype coupled to the muscarinic acetylcholine receptors is responsible for 
this response (81). Adenylyl cyclase catalyzes the breakdown of ATP into cAMP, 
which in turn can activate cAMP-dependent protein kinases (PKA). Some studies 
have shown that the expressed M1 subtype can weakly couple to adenylyl 
cyclase inhibition through a PTX-sensitive mechanism like in RAT-1 cells (82), 
while on the other hand previous reports have shown that the endogenous M3 
subtype can cause an accumulation of cAMP in several other cell types (83, 84, 
85). Also the βγ-subunits of the G-proteins coupled to the M1 and the M5 
muscarinic receptors can also weakly stimulate adenylyl cylcase (86, 87). The 
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coupling of muscarinic receptors to adenylyl cyclase activation can also be 
regulated through calcium and protein kinase mechanisms (88, 89). cAMP 
production may occur through calcium/calmodulin sensitive (type I and type III) or 
insensitive (type II, IV, V and VI) adenylyl cyclases. The adenylyl cyclase type 
coupled to the muscarinic receptors is dependent on the cell line in which they 
are expressed. Nevertheless, the accumulation of cAMP may actually be the 
result of muscarinic receptors mediated phosphodiesterase inhibition as 
observed in a variety of cell types (90).  
   
1.4.2 Phospholipase C 
The phospholipid isoenzymes of particular interest with regard to muscarinic 
acetylcholine receptor signaling pathways are the phospholipases C, A and D 
(PLC, PLA and PLD). The family of PLC enzymes is grouped into three classes 
β, γ, and δ, with subtypes within each group (91). The receptor-mediated 
activation of the PLC lead to the hydrolysis of the phosphotidylinositol-4,5-
biphosphate (PIP2) to inositol triphosphate (IP3) and diacylglycerol (DAG), which 
in turn mediate the activation of  intracellular calcium release and protein kinase 
C activation respectively. Phosphoinositide breakdown by acetylcholine has been 
well studied and linked to M1/M3/M5 muscarinic receptors through the coupling of 
Gq/11 protein, while M2 and M4 subtypes have been reported to weakly activate 
PLC (92). In the case of M1 subtype, the phosphoinositide breakdown is 
mediated by PLCβ1 through Gq/11 alpha subunits (93, 94, 95). On the other hand, 
the M5 subtype has been linked to the activation PLCβ and PLCγ. PLCγ 
activation is normally stimulated by tyrosine kinase-dependent phosphorylation, a 
mechanism induced by M5 mediated calcium influx that activates voltage-
independent calcium channels and subsequent tyrosine kinase phosphorylation 
(96). However the M2 subtype did not stimulate the phosphorylation of PLCγ or 
mediation of calcium influx. Later studies have shown, though, that the M2 and 
M4 receptors can also stimulate with lower efficiency phospholipase C through a 
PTX-sensitive G-protein, namely through Gα2 and Gαi3 (86, 97). Also βγ-subunits 
were shown to couple M2 receptors and phospholipase Cβ2 (98). In another 
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study it was observed that protein kinase C (PKC) seemed to play a regulatory 
role in the muscarinic acetylcholine receptor mediated accumulation of inositol 
triphosphate (99). IP3 can act on its respective receptor in the endoplasmic 
reticulum (an IP3-sensitive calcium channel), releasing calcium from its 
intracellular store, while DAG, can activate with cooperation of calcium and 
certain isoenzymes of PKC.  PKC consist of three subgroups: the classical, 
which include α, βI, βII and γ isoenzymes that are activated by DAG and calcium, 
the novel, which include δ, ε, θ, η, μ, and are activated by DAG alone,  the 
atypical, which include ζ,  λ, L, and are independent of both calcium and DAG 
(100). It should be noted that certain isoenzymes are involved in stimulating 
proliferation (101), while others are involved in negatively regulating muscarinic 
acetylcholine receptor activity by phosphorylating sites on the i3 loop (60).  
 
1.5 Mitogen Activated Protein Kinases 
Mitogen-activated protein kinase (MAPK) pathways regulate diverse processes 
ranging from proliferation and differentiation to apoptosis. It is activated by both 
tyrosine kinase receptors as well as G-protein coupled receptors. The core of the 
MAPK cascade consists of an evolutionally conserved module of three 
sequentially activated protein kinases. The activation of the MAPK requires 
phosphorylation on conserved tyrosine and threonine residues localized to the so 
called activation loop, and is catalyzed by a dual specificity MAPK kinase 
(MAPKK). MAPKK, in turn, is under the control of a MAPKK kinase (MAPKKK), 
which in turn, is regulated by G-proteins and in some cases, by a MAPKKK 
kinase (MAPKKKK). Three of these modules are present in the mammalian cells: 
extracellular signal regulated kinases (ERK1 and ERK2) which are also known as 
p42MAPK and p44MAPK, N-terminal c-Jun kinases (JNKs) and p38MAPKs. 
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Figure II Schematic view of MAPK signaling pathways in mammalian cells. 
 
 
ERKs, were the first to be cloned and their actions have been best examined in 
the context of growth factor signaling via receptor tyrosine kinases (RTKs). The 
archetypal ERK cascade involves the activation of small GTPase Ras upon 
agonist stimulation of the RTK receptors. This stimulation leads to the 
autophosphorylation of the RTK in tyrosine residues and recruitment of adaptor 
proteins bearing SH2 and SH3 motif (Shc and Grbr2) that bind to an exchange 
factor for Ras, SOS. SOS allows nucleotide exchange dependent activation of 
the MAPKKK Raf-1. Raf-1 is a kinase with a serine/threonine specificity that 
catalyzes the activating phosphorylation of MEK1/2, which ultimately 
phosphorylates ERK1/2 on its activation loop (Figure II). Amplification via this 
signaling cascade is such that it is estimated that activation of solely 5% Ras 
molecules is sufficient to induce a full activation of ERKs (102). In resting cells, 
ERKs are anchored in the cytoplasm via association with MEK1/MEK2, but 
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following activation they dissociate from the cytoplasmatic anchoring complex 
and enter the nucleus, the site for signal termination (103).  
The second group of MAPKs, JNK proteins, were first described as kinases that 
phosphorylate serine residues on the N-terminus c-Jun transcription factor 
following UV exposure. The third subgroup p38, were found to be activated in 
response to different forms of stress. Both JNK and p38 are given the more 
clarifying name SAPKs (stress activated protein kinases). Rho family members 
(Rho, Rac, Cdc42) are thought to be involved in SAPK activation in response to 
cytokines or cellular stress (104).    
 
1.5.1 MAPKs in the Regulation of Cell Cycle 
The cell cycle is controlled by a class of nuclear enzymes called cyclin-
dependent kinases (CDKs), expressed constitutively but present in inactive form 
unless combined with their cyclin partners. The stimulatory effects of cyclins are 
counteracted by the inhibitory effects of CDK inhibitory proteins (CKIs), of which 
two families are well described: INK4 and Cip/Kip (p21) (105). Progression 
through G1 phase is especially affected by extracellular signals, and is regulated 
by CDK4/CycD, CDK6/CycD and CDK2/CycE complexes. Most studies indicate 
that integrins and growth factors, by activating MAPK pathways, typically control 
expression of Cyclin D1 and/or downregulate CKIs. In this regard, the activation 
of MAPK/ERK pathway has been linked to the induction of cyclin D1 
transcription, since expression of dominant negative mutants of MEK and ERK 
prevented growth-factor dependent transcription of the Cyclin D1 gene (106). 
The formation of active CyclinD/CDK4 complex is considered rate-limiting for cell 
growth (107, 108). Recent studies indicate the critical determinant in the 
induction of Cyclin D1 is the duration of the ERK signal. Activation of ERK can be 
transient or sustained, depending on the stimulus. For example, serotonin 
induced a transient (10 min) stimulation of ERK in the CCL39 cells (Chinese 
hamster lung fibroblast cell line); while thrombin induced a far more sustained 
activation that peaks 3-4 hours after addition to cells (109). Some studies have 
observed a correlation between the strength of the mitogenic signaling and the 
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duration of ERK stimulation. While non-mitogenic factors induce a transient 
activation of ERKs (less than 15 mins) that does not lead to cell cycle entry, 
mitogens induce cell proliferation and sustained ERK activation (up to 6 hrs) 
(110). 
From these studies, an important link between MEK/ERK pathway and cell cycle 
machinery was established, and furthermore, that sustained ERK activation was 
a common characteristic elicited by mitogens that would permit entry and 
progression through G1 phase of cell cycle (Figure III) 
 
Figure III Cell cycle progression. ERKs phosphorylates transcription factors turning on the 
expression of target genes, including Cyclin D (CycD). Association of CycD with its cyclin 
dependent kinase partners (CDKs), results in phosphorylation of retinoblastoma protein (pRB). Its 
phosphorylation is required for progression through G1 phase of cell cycle. Other Cyclin/CDKs 
complexes (CycE/CDK2, CycA/CDK2) are required for progression through late G1 and S 
phases. 
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1.6 G-protein Coupled Receptor Signaling to MAPK 
Activation of MAPKs mediated by G-protein-coupled receptors has been 
extensively studied, including investigation on bombesin, endothelin-1, 
adrenaline, somatostatin, thromboxane A2, and muscarinic receptors. These 
receptors have been shown to couple to PTX-sensitive and PTX-insensitive G-
proteins, thus signaling to MAPK using both G-proteins (Gi/o and Gq/11). To study 
the mechanism of activation of MAPK by G-protein-coupled receptors such as 
muscarinic acetylcholine receptors, transfected cell lines that express p42mapk 
(labeled as MAPK in this text) together with muscarinic acetylcholine receptor 
subtypes were used (111). In transfected cell lines like COS-7 carbachol 
stimulation increased MAPK activity in a concentration dependent manner 
through M1 and M2 subtypes (112), whereby the M1 mediated activation was 
PTX-insensitive, while the M2 mediated activation displayed PTX-sensitivity. To 
elucidate the role of the α-subunits of G-proteins, studies were performed in 
transfected cells expressing wild-type or activated G-protein α-subunits, including 
Gαq and Gαi2 which couple M1 and M2 subtypes respectively. However, these 
transfected cells did not exhibit elevated MAPK phosphorylating activity. As a 
result leading to speculations of molecules in addition to α-subunits of G-proteins 
playing a role in M1 and M2 mediated MAPK activation. 
Recently available evidence has supported an active role for the Gβγ complex in 
signal transduction (113). Since α-subunits did not stimulate the activation of 
MAPK, studies investigating the role of Gβγ-subunits were performed. Indeed, 
transfecting cells with β1 and γ2 subunits and MAPK effectively elevated it 
phosphorylating activity demonstrating that the βγ heterodimers directly elicits 
biochemical pathways leading to MAPK activation. Also, sequestration studies 
performed on βγ complexes by overexpressing Gαi proteins abolished the M2 
and βγ-mediated activation of MAPK, and reduced this response when elicited by 
M1 stimulation. Therefore, these results indicate that M1 signaling to MAPK 
involves βγ-dependent and independent pathways; while M2 mediated activation 
of MAPK appears to be strictly dependent on Gβγ. 
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Mutant-Ras studies were performed to investigate whether signaling from M1 and 
M2 receptors or βγ dimmers involves p21ras (Ras).  These studies have shown 
that mutant Ras expression abolished the elevated MAPK activity in response to 
M1, M2 and βγ dimmer overexpression (114, 115). Similar studies were done to 
elucidate the role of PKC, and the results suggested that signaling from M1 
receptors to MAPK involves a PKC-dependent and PKC-independent pathway, 
and both pathways converge at Ras. The PKC-independent pathway is mediated 
by the Gβγ complex. On the other hand the M2-mediated MAPK activation is PKC-
independent, and involves Giβγ dimmers, acting on a Ras-dependent pathway.  
 
1.7 Intracellular Signaling Pathways Linking G-protein Coupled Receptors 
to MAPK 
Activation of a given type of G-protein-coupled receptor (GPCR) triggers a limited 
set of signaling events in a very rapid and specific manner. The classical 
paradigm of GPCR signaling was rather linear and sequential. Emerging 
evidence, however, has revealed that this is only a part of the complex signaling 
mediated by GPCR. Propagation of GPCR signaling involves cross-regulation of 
many but specific pathways; including cross-talk between different GPCRs as 
well as with other signaling pathways and that the MAPK activation appears to be 
a common point of convergence for most of these pathways (Figure IV). A few of 
these signaling cascades relevant to the present study will be elucidated in this 
paper. 
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Figure IV GPCR mediated activation of MAPK regulated by generation of intracellular 
second messengers. GPCR activity leads to AC/cAMP (Adenylyl cyclase/cyclic adenosine 
monophosphate), and PLCβ/PKC (Phospholipase C/Protein kinase C) second messenger 
pathways. cAMP directly, or via PKA (Protein kinase A), activates RAP-1/B-Raf/ERK pathway, 
and potentially inhibits Raf-1 activated ERK activity. The Gαq/PLCβ/PKC promotes Ras/Raf-
1/ERK activity, and it is likely that Gq and Gi/o coupled GPCRs can activate JNKs and p38. The 
result of the interplay between these pathways is either proliferative or antiproliferative, 
depending on the expression of GPCRs and signaling intermediates. Dashed indicators identify 
the probable involvement of multiple, unidentified intermediates. (New and Wong 2007)  
 
 
1.7.1 The Ras Mediated Activation of MAPK Cascade via G-protein Coupled 
Receptors 
Ras belongs to the family of small GTPases which exhibit high-affinity binding for 
GDP and GTP, and possess low intrinsic GTP hydrolysis and GDP/GTP 
exchange activities. The GDP/GTP cycling is controlled by two main classes of 
regulatory protein. Guanine-nucleotide-exchange factors (GEFs) promote 
formation of the active GTP-bound form (116), whereas GTPase-activating 
proteins (GAPs) accelerate the intrinsic GTPase activity to promote the formation 
of the inactive GDP-bound form. A second important biochemical feature of Ras 
proteins is their post-translational modification by lipids. The Ras proteins 
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terminate with a C-terminal CAAX (C=cysteine, A=aliphatic, X=any amino acid) 
tetrapeptide sequence (117). This motif, when coupled together with residues 
immediately upstream (e.g. cysteine residues modified by the fatty acid 
palmitate), comprises the membrane-targeting sequences that dictate 
interactions with distinct membrane compartments and subcellular locations. The 
CAAX motif is the recognition sequence for franesyltransferase and 
geranylgeranyltransferase, which catalyze the covalent addition of a franesyl or 
geranylgeranyl isoprenoid, respectively, to the cysteine residue of the 
tetrapeptide motif. These modifications are essential for facilitating membrane 
association and subcellular localization critical for biological activities. Ras 
proteins serve as signaling nodes activated in response to diverse extracellular 
stimuli. Activated Ras interacts with multiple, catalytically distinct downstream 
effectors, which regulate cytoplasmic signaling networks that control gene 
expression and regulation of cell proliferation, differentiation, and survival. 
Lysophosphatidic acid (LPA) and thrombin were the first GPCR agonists shown 
to rapidly stimulate Ras-GTP accumulation in quiescent mammalian cells (118).  
However the best characterized Ras signaling pathway is activation of Ras by 
the epidermal growth factor receptor tyrosine kinase through the RasGEF Sos 
(119). Activated Ras binds to and promotes the translocation of the Raf 
serine/threonine kinase to the plasma membrane, where additional 
phosphorylation events promotes full Raf kinase activation. Raf phosphorylates 
and activates MEK1/2 dual specificity protein kinase, which phosphorylates and 
activates the ERK1/2 mitogen-activated protein (MAP) kinase. Activated ERK 
translocates to the nucleus, where it phosphorylates transcription factors leading 
to gene transcription and cell cycle progression. In quiescent fibroblast it was 
seen that LPA mediated Ras activation via pertussis toxin sensitive Gi protein 
(118) and also in certain cell type’s α2 adrenergic receptors could similarly 
activate Ras via Gi protein hence suggesting that Ras activation might be a 
common event in the action of Gi-coupled receptors (120). Furthermore in Rat 1a 
fibroblasts cells expressing the pertussis toxin-sensitive G-protein α subunits αi2 
and αi3 but not αo, muscarinic M2 receptor stimulation resulted in activation of 
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Ras-Raf-MAPK, implicating the involvement of the Gi protein in this pathway 
(121). Various studies have shown that Gαi directly binds to and inhibits adenylyl 
cyclase, thereby lowering cytosolic cAMP levels and since the rise of cAMP 
levels inhibits the Ras-MAPK pathway, apparently at the level of Ras-Raf 
interaction (122, 123) it is conceivable that a Gαi mediated fall in cAMP levels 
may positively influence Ras-Raf coupling.  
The classic Gαq-PLC-Ca2+/PKC pathway can also mediate MAPK activation, 
either via Ras or independent of Ras. Certain Ras specific GEFs can activate 
Ras in response to PLC-generated messengers such as Ca2+ and DAG, which 
bind directly to these GEFs (124, 125, 126, 127). In cells expressing these GEFs, 
Ras can thus be activated by PLC activation in a Grb2-Sos-independent manner. 
Furthermore several PKC isoenzymes can phosphorylate and activate c-Raf 
independently of Ras (128, 129). PKC activation by phorbol ester leads to Ras 
activation in COS epithelial cells and in neonatal myocytes (130, 131), but this 
pathway apparently does not function in fibroblasts (118). 
Raf proteins are the conserved signaling module that transducer signals from the 
cell surface to the receptor wherein the Ras family of small G-proteins are the 
upstream regulators in several cell types.   However, it has been shown that 
activation of MAPK cascade  can occur through Ras-independent  mechanisms 
involving Raf for example,  in rat C6 glioma cells activation of the purinergic 
P2YAC-receptor a GPCR,  by using specific agonist activated MAPK through a Gi-
RhoA-PKC-Raf-MEK-dependent but a Ras and Ca2+ independent cascade (132). 
Another mechanism that has been suggested in the Ras-independent activation 
of Raf involves the activation of C-Raf by p21-activated kinases (PAK). PAKs are 
serine/threonine specific kinases that bind to and are activated by, the membrane 
bound Rho-family GTPases Cdc42 and Rac, and it has been proposed that these 
kinases lead to C-Raf activation in a Rac/Cdc42-and phosphatidylinositol-3-
kinase (PI3K)-dependent manner. Although the physiological significance of this 
PAK-mediated C-Raf activation is not established, the PAK-dependent Ras-
independent route to C-Raf activation might have an important role in C-Raf 
activation by inetgrins or when microtubules are disrupted (133). 
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1.7.2 Rho Mediated Activation of MAPK Cascade via G-protein Coupled 
Receptors 
Like Ras, Rho proteins also serve as key regulators of extracellular-stimulus-
mediated signaling networks that regulate actin organization, cell cycle 
progression and gene expression (134). Twenty members have been identified, 
RhoA, Rac and Cdc42 being the best studied. The guanine-nucelotide-exchange 
factors (GEFs) and GTPase-activating proteins (GAPs) control the activation of 
the small GTPases Rho, Rac and Cdc42. Once activated the GTPases bind to a 
spectrum of effectors to stimulate downstream signaling. Rho kinase 1 (ROCK1) 
and ROCK2 are key Rho effectors that have multiple substrates. Most GPCR 
agonist that regulate actin cytoskeletal responses, smooth muscle contraction, 
gene transcription, and cell growth through Rho-dependent pathways can couple 
to more than a single class of heterotrimeric G-protein. For example LPA and 
thrombin elicit cellular responses through both pertussis toxin-sensitive and 
insensitive G-proteins. Furthermore GPCR agonists have been also shown to 
mediate Rho activation through the Gαq and Gα12/13 subtypes of the G-protein 
family (135).GPCRs including the thrombin receptor in platelets and LPA 
receptors in Swiss 3T3 cells have been shown to activate PI3K, and studies 
using C3 exoenzyme indicates this requires Rho function (136, 137). It has been 
shown that M1 and M2 muscarinic receptor stimulation can lead to 
phosphorylation and activation of a serine/threonine protein kinase Akt/PKB 
(138). Akt/PKB (protein kinase B) is regulated through PI3K and synthesis of 
PIP2 and PIP3 (139). Thus it is possible that GPCRs utilize Rho to regulate this 
cell survival pathway. Various studies have demonstrated that Rho-dependent 
signaling is required for transformation by oncogenic Ras (140, 141, 142). 
However, while Rho activation is known to promote the development of stress 
fibers and focal contact, Ras-transformed fibroblast generally exhibit a loss of 
these structural elements characteristic of Rho activity. These results have lead 
to the interpretation that Rho activity may be reduced in Ras-transformed cells. 
Accordingly, activated Rho can restore stress fibers in Ras transformed Rat1 
fibroblasts, suggesting that Rho can be inactivated in these Ras-transformed 
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cells (143). By contrast, inhibition of Rho kinase was shown to block Ras 
transformation in NIH3T3 cells (144) and to attenuate invasive tumor cells (145). 
In another study done on vascular smooth muscle cells (VSMC) from rat aorta it 
was seen that thrombin stimulated DNA synthesis and migration were inhibited 
by exoenzyme C3 and Y27632 a Rho kinase inhibitor. Although thrombin 
activates RhoA, and Rho is necessary for thrombin-stimulated DNA synthesis in 
rat aortic VSM, adenoviral transfection of cells with activated RhoA was found not 
to be sufficient to induce DNA synthesis. Rather, for mitogeinic signaling in 
VSMC, it appears that RhoA collaborates synergistically with Ras, such that DNA 
synthesis is activated only by agonists that stimulate both pathways (146). This 
supports studies indicating that activation of Rho is critical for Ras-induced cell 
cycle progression. Thus the relationship between Ras and Rho dependent 
signaling pathways during transformation is still unclear. A role for Rho in 
regulating cell proliferation was first suggested by studies in which it was 
demonstrated that C3 mediated inhibition of Rho caused fibroblasts to arrest in 
the G1 phase of the cell cycle (147). One downstream effect of Rho is to reduce 
expression of cell cycle inhbitor such as the cyclin-dependent kinase inhibitors 
p21Waf1/Cip1 and p27Kip1 in studies done on rat aortic VSMC it was demonstrated 
that adenoviral expression of a constitutively active form of RhoA reduced p27Kip1 
protein levels. Direct activation of Rho with cytotoxic necrotizing factor-1 also 
decreases p27Kip1 and increases DNA synthesis in human smooth muscle cells 
(148). In another study it was shown that serotonin stimulation of bovine 
pulmonary artery VSMC leads to translocation of ERK to the nucleus, and this 
response is inhibited by treatment with either dominant negative RhoA or the Rho 
kinase inhibitor Y27632 (149). Furthermore it was reported that cyclin D1 
expression is deregulated through a RhoA dependent mechanism that influences 
human lung fibroblast proliferation.   
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1.7.3 Phosphatidylinositol 3-Kinase (PI3K) Mediated Activation of MAPK 
Cascade via G-protein Coupled Receptors 
Phosphoinositides (PIs) are rare lipids. Phosphoinositide 3-kinases (PI3Ks) are a 
family of related enzymes that are capable of phosphorylating the 3 position 
hydroxyl group of the inositol ring of phosphatidylinositol (PtdIns). PI3Ks are 
structurally diverse enzymes divided into three main classes. Each class exhibits 
distinct substrate specificity. Class IA PI3-kinases is a cytosolic heterodimer 
composed of a 110-kDa (p110α, -β, or –δ) catalytic subunit and an 85-kDa (p85) 
adaptor protein. In response to growth factors stimulation, class IA PI3-kinases 
complex with activated receptor protein tyrosine kinases (through SH2 domains 
of the p85 subunit) or tyrosine-phosphorylated proteins. The class IB PI3-
kinases-γ does not have an adaptor protein but instead is activated by the Gβγ 
subunits of the G-proteins (150). Class II PI3-kinases contain a COOH-terminal 
C2 domain that appears involved in regulation of this class by phospholipid and 
calcium (151). Recently Class III PI3-kinases have been also identified.  It has 
been shown that receptor tyrosine kinase (RTK) and GPCR both can activate 
class I PI3Ks via phosphorylation steps which leads, through an adaptor 
molecule, to the recruitment of PI3K to the membrane. Once activated and 
localized to the membrane, PI3K phosphorylates phosphoinositol lipids on the D3 
position of the inositol ring generating PtdIns-3-phosphates (PtdIns-3,4-P2 and 
PtdIns-3,4,5-P3). These specialized lipids serve to recruit pleckstrin homology 
(PH) domain-containing proteins such as the serine-threonine kinase Akt (protein 
kinase B) and PDK1 (phosphoinositide-dependent kinase 1) to the plasma 
membrane. After recruitment to the membrane Akt is phosphorylated and 
consequently activated, by PDK. In turn, Akt phosphorylates multiple proteins on 
serine and threonine residues. Through phosphorylation of these targets, Akt 
carries out its role as a key regulator of a variety of critical cell functions including 
glucose metabolism, cell proliferation and survival. Besides being a downstream 
effector of PI3-kinases, Akt may also be activated in a PI3-kinase-independent 
manner. Studies have suggested that cAMP-elevating agents could activate AKT 
through protein kinase A (PKA), although these studies are disputed and the 
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mechanism of action is unclear. The PI3K dependent Akt activation is regulated 
through PTEN which acts as a phosphatase to dephosphorylate PtdIns (3,4,5)P3 
back to PtdIns(3,4)P2. This removes the membrane-localization factor from the 
Akt signaling pathway thus inhibiting downstream pathways dependent on Akt 
activation.  
 
Figure V Activation of PI3K-dependent cell cycle regulation. The expression, stability and 
activity of cyclin and CDK inhibitors are regulated by the activity of several PI3K-dependent 
pathways. Numerous GPCRs activate PI3K isoforms either through Gβγ subunits or via receptor 
tyrosine kinase (RTK) and integrin transactivation. PI3Ks activate ERK and Akt, leading to the 
transcriptional regulation of p27Kip1. In addition Akt phosphorylates p27Kip1, thereby affecting its 
nuclear localization. Acting through TSC1, TSC2 and mTOR (mammalian target of rapamycin), 
Akt can negatively affect the stability of p27Kip1, although GPCR regulation of proliferation through 
mTOR has not been established (indicated by dashed line). PI3Ks may also promote proliferation 
by promoting cyclin expression (via p70S6K). (New and Wong 2007) 
 
  
Following direct or indirect GPCR-induced PI3K activation, cell cycle progression 
is regulated by the effects of PI3K activated kinases on the expression and 
stability of cell cycle proteins, or by the modulation of the activity of other signal 
transduction pathways (Figure V). For example, thrombin receptor activation in 
vascular smooth muscle cells lead to reduced levels of p27Kip1 and increased 
proliferation (152), while in embryonic fibroblast the evidence suggests that 
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thrombin receptor activation of PI3K/Akt pathways promotes cyclin D1 
accumulation, cyclin D1-CDK4 activity and cell cycle progression (153, 154). 
Furthermore, it has been postulated that thrombin receptor activation of ERK 
ultimately leads to enhanced translocation of CDK2 into the nucleus and 
fibroblast proliferation (155). In another study overexpression of phosphoinositide 
3-kinase γ (PI3Kγ) in COS-7 cells expressing M2 muscarinic receptors, agonist 
induced Gβγ-subunit dependent MAPK activation via transactivation of tyrosine 
kinase receptors in a Sch-Grb2-Sos-Ras-Raf-MAPK manner. Expression of a 
catalytically inactive mutant of PI3Kγ abolished this stimulation of MAPK by the 
Gβγ or in response to stimulation of muscarinic M2 G-protein-coupled receptors. 
Indicating that, PI3Kγ mediated Gβγ-dependent regulation of the MAPK signaling 
pathway (156). 
 
1.7.4 Phospholipase C (PLC) Mediated Activation of MAPK Cascade via G-
protein Coupled Receptors 
The receptor-mediated activation of the PLC lead to the hydrolysis of the 
phosphotidylinositol-4,5-biphosphate (PIP2) to inositol triphosphate (IP3) and 
diacylglycerol (DAG), which in turn mediate the activation of  intracellular calcium 
release and protein kinase C activation respectively. Phospholipase C (PLC) is 
the principal effector of Gq-mediated signaling. Eleven different isoforms of PLC 
exist and exhibit distinct patterns of regulation; members of the PLCβ subfamily 
tend to mediate the actions of activated Gq (157). It has been shown that 
activation of PKC isoforms by Gq/11-dependent regulation of phospholipase Cβ 
can also lead to MAPK activation through both Ras-dependent and Ras-
independent mechanisms. In another study it was demonstrated that PKCα can 
apparently activate Raf-1 by direct phosphorylation thus activating the MAPK 
cascade (158). In cells of neuronal origin, Gq/11-dependent activation of the 
calcium and focal-adhesion-dependent focal adhesion kinase family member 
Pyk2, leads to Ras-dependent ERK activation (159). In this system, intracellular 
calcium, released as a result of PLCβ-mediated inositol triphosphate production, 
triggers Pyk2 autophosphorylation, recruitment of nonreceptor tyrosine kinase c-
25 
Src, tyrosine phosphorylation of Sch, and Ras-dependent ERK activation (160, 
161). Activation of ERK1/2 by M1, M3 and M5 muscarinic receptors typically 
involves PKC activation following Gq/11 activation of the PLC pathway with 
production of DAG. For example, in human neuroblastoma SK-N-BE2(C) cells 
activation of ERK1/2 by M3 muscarinic receptors was dependent on PKCε as well 
as the guanine nucleotide exchange factor, Ras and the Raf family of serine-
threonine kinases (162).   
 
1.8 Transactivation of Classical Receptor Tyrosine Kinases by GPCRs 
Receptor transactivation refers to the ability of a primary agonist, via binding to 
its receptor, to activate a receptor for another ligand via signaling events. 
Transactivation of various growth factor receptors, including the epidermal 
growth factor receptor (EGFR), and the platelet derived growth factor (PDGF), by 
G-protein-coupled receptors has been documented in multiple cellular model 
systems (163, 164, 165, 166, 167). Receptor transactivation can potentially occur 
through several different mechanisms. One mechanism is through activation of 
intracellular protein tyrosine kinase, such as c-Src and PKC (168, 169), which 
can phosphorylate the growth factor receptor and thereby promote its activation. 
GPCR-induced transactivation of the EGFRs has been studied in some detail. 
GPCR activation leads to cleavage of the pro-EGF (eg pro-heparin-binding-EGF) 
ligands from the membrane initiating the transactivation (168, 170, 171). 
Proteolysis of the HB-EGF precursor is thought to be mediated by members of 
the ADAM family of matrix metalloproteases (MMPs) (172). The step that is 
stimulated by GPCRs has not been identified. EGFR transactivation has been 
shown to occur primarily through shedding of HB-EGF from the membrane (173, 
174). Transactivation of EGFR results in intracellular signaling that leads to 
growth, proliferation, and migration. In fibroblasts, both Gi/o-coupled and Gq/11-
coupled receptors have been shown to stimulate HB-EGF release. For Gi/o-
coupled receptor, such as the LPA (112), α2A adrenergic (175) and M2 
muscarinic acetylcholine receptors (176), HB-EGF shedding and EGFR 
transactivation are mediated by the Gβγ subunits of the heterotrimeric G-proteins 
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(177). HB-EGF shedding in response to stimulation of the Gq/11-coupled 
receptors, such as enodthelin-1 and α-thrombin receptors (178), mediated by the 
Gq/11α-subunits (179, 180). The G-protein effectors that regulate ectodomain 
sheddin remain unidentified, although PI3Ks (156) and Src family nonreceptor 
tyrosine kinases have each been proposed as early intermediates in the EGFR 
transcativation pathway (177, 181). 
 
1.9 Apoptosis and G-protein Coupled Receptor Signaling Interaction 
Apoptosis is defined as a genetically controlled mechanism of cell death involved 
in the regulation of tissue homeostasis and morphologically characterized by cell 
shrinkage, membrane remodeling and blebbing, chromatin condensation and 
DNA and cellular fragmentation into apoptotic bodies. Pro-apoptitic singaling may 
be mediated by the specific ligands and surface receptors, which are capable of 
delivering death signal from the microenvironment and can activate the 
excecution of apoptosis in the cell cytoplasm and organelles. Apoptosis can also 
be activated from inside the cell through specific cell sensors residing in the cell 
nucleus and cytoplasm. Both these pathways of apoptosis signaling converge 
into a common pathway causing the activation of effectors termed caspases 
(182). Caspases are a family of cysteine proteases that cleave their substrates at 
aspartic acid residues (183). They are hierarchically stratified into upstream 
initiator caspases, namely procaspases 8, 9, 10 and downstream the effector 
caspases 3, 6, 7, caspase-3 activity in particular is the common effector of most 
apoptotic pathways. Besides the caspases, members of the Bcl-2 protein family 
are also critical for the regulation of apoptosis. Both anti-apoptotic (BCL-2, Bcl-w, 
Bcl-xL) and pro-apoptotic (Bax, Bak, Bad) Bcl-2 family members have been 
identified (184). Studies have shown that ERK family of the MAPKK may also 
have anti-apoptotic effects when activated by the growth factor receptors. The 
proposed pathway for ligand binding to growth factor receptors initiating an anti-
apoptotic signaling is via the activation of Raf which in turn activates ERK1/2 
which could phosphorylate Bcl-2 in a manner that stabilizes its anti-apoptotic 
activity. Another mechanism is via the activation of Rsk, which phosphorylates 
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the pro-apoptotic protein Bad leading to its inactivation thus promoting cell 
survival. 
The repertoire of signaling pathways controlled by GPCRs has recently been 
extended by studies linking GPCRs to the regulation of apoptosis. Depending on 
the receptor subtypes and the cell type in which the receptor is expressed, 
GPCRs can either induce apoptosis or protect cells from apoptotic stimuli. For 
example β1-adrenergic receptors in cardiac myocyctes can induce apoptosis 
through a Gs-mediated pathway, whereas β2-adrenergic receptors in the same 
cell type can protect cells through a Gi-mediated mechanism (185). Prominent 
among the GPCRs that protect cells from apoptotic stimuli are the subtypes of 
the muscarinic receptor family (186, 187). Previous studies have also shown that 
muscarinic receptors that couple to the Gq/11 protein (e.g. M1, M3 and M5) can 
protect cells from apoptosis following DNA damage whereas those coupled to the 
Gi-proteins (M2 and M4) have no protective properties (188). In a study done 
using CH (Chinese-hamster ovary) cells it was shown that the M3 muscarinic 
receptor anti-apoptotic effect is independent of calcium/phospholipase C 
signaling but proceeds in a manner that involves both gene transcription and the 
up-regulation of the anti-apoptotic Bcl-2 protein.  
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2 Materials and Methods 
2.1 Materials 
2.1.1 Reagents 
Agarose    Serva Roth 
BSA                                                                             Bio-Rad 
Bromophenol blue                                                      Sigma-Aldrich 
Chemiluminescence Blotting Substrate (POD)           Bio-Rad 
Disodium hydrogen orthophosphate (Na2HPO4) Merck 
Desoxynucleotide mixture Sigma-Aldrich 
DNA Smart-Ladder                                                      Eurogene Tech 
Developing Solution                                                   Sigma-Aldrich 
ECL Detection Kit                                                       Boehringer Ingelheim 
Ethidium Bromide                                                  Sigma-Aldrich 
Ficoll 400, Type 400 Sigma-Aldrich 
Fixing Solution                                                          Sigma-Aldrich 
Fetal Calf Serum (FCS)                                         Seromed 
Kaleidoscope Marker                                                 Sigma-Aldrich 
Leupeptin                                                                  Sigma-Aldrich 
Lowry Kit                                                                   Bio-Rad 
Lumasafe scintillation cockt Lumac 
MEM Non Essential Amino Acids (100 x) = NEAA PAA 
β-Mercaptoethanol Sigma-Aldrich 
(Methyl-3H)-Thymidine 37 mBq/ml PerkinElmer 
Nonidet P-40                                                            Sigma-Aldrich 
Oligo dT-Primer MWG-Biotech 
Omniscript RT Kit: Qiagen 
Penicillin / Streptomycin solution                        Sigma-Aldrich 
(10000 U/ml / 10 mg/ml)       
 Platelet derived growth factor = PDGF Sigma-Aldrich 
Pepstatin A                                                                 Sigma-Aldrich 
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Phenylmethylsulphonylfluoride (PMSF)                   Sigma-Aldrich 
Ponceau S                                                     Boehringer Ingelheim 
RNase-Free DNase Set Qiagen 
RNase Inhibitor RNasin Plus 40 U/µl Promega 
RNeasy Mini Kit Qiagen 
RNeasy Tissue Kit Qiagen 
Roti-Load 1                                           Roth 
Sodium chloride (NaCl) Roth 
Sodium hydroxide pellets (NaOH) Merck 
Sodium Pyrovate Solution = SPS (100mM) PAA  
Streptomycin                                                             Sigma-Aldrich 
TaqDNA Polymerase 5 U/µl Invitrogen 
Trichloro-acetic acid crystals (TCA) Merck 
Tris (Tris-(hydroxymethyl-aminomethane) Roth 
Tris-HCl (Tris-(hydroxymethyl)-aminomethane        Boehringer Ingelheim 
hydrochloride)        
Triton x-100 Boehringer Ingelheim  
Trypthan Blue (0,4 %) Sigma-Aldrich 
Trypsin EDTA 10 Sigma-Aldrich 
Tween 20                       Sigma-Aldrich 
 
2.1.2  Test Drugs 
 
Atropine sulphate (10 mM)                                   Sigma-Aldrich 
Stock solution prepared in  sterile water, further dilutions were done with sterile 
water 
 
Actinomycin D (1 mg/ml)                                            Sigma-Aldrich 
Stock solution prepared in DMSO, further dilutions were carried out with sterile 
carried 
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AF-DX 384 (10 mM)                                    Boehringer Ingelheim 
(5,11-dihydro-11-{[(2-{2-[(dipropylamin)methyl1]-1-
piperidinyl}ethyl)amino]carbonyl1}-6H-pyrido(2,3-ß) (1,4)benzodiazepine-6-one 
methanesulfonate) 
Stock solution prepared in sterile water, further dilutions were done with sterile 
water 
 
AQ-RA 741 (10 mM)                Boehringer Ingelheim 
(11-({4-[4-(diethylamino)butyl]-1-piperidinyl}acetyl)-5,11-dihydro-6H-pyrido(2,3-ß) 
(1, 4)benzodiazepine-6-one hydrochloride) 
Stock solution prepared in sterile water, further dilutions were done with sterile 
water 
 
Carbachol (10 mM)                    Sigma-Aldrich 
(Carbamylcholine chloride) 
Stock solution prepared in sterile water, further dilutions were done with sterile 
water  
 
Cycloheximide (1 mg/ml)                                     Sigma-Aldrich 
Stock solution prepared in sterile water, further dilutions were done with sterile 
water 
 
4-DAMP (10 mM)                                          Sigma-Aldrich 
(4-diphenylacetoxy-N-methylpiperidine methoiodide) 
Stock solution prepared in sterile water, further dilutions were carried out with 
sterile water 
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FTI-277 (10 mM)                              Calbiochem 
(Methyl{N-[2-phenyl-4-N[2(R)-amino-3-mecaptopropylamino]benzoyl]}-
methionate,TFA) 
Stock solution prepared in DMSO, further dilutions were performed with sterile 
water 
 
GW 5074 (20 mM)                                           Tocris 
(3-(3,5-Dibromo-4-hydroxy-benzylidene)-5-iodo-1,3-dihydro-indol-2-one) 
Stock solution prepared in DMSO, further dilutions were done with sterile water 
  
Himbacine (10 mM)                                         Sigma-Aldrich 
Stock solution prepared in ethanol, further dilutions were performed with sterile 
water 
 
Hexamethonium Bromide (10 mM)                     Sigma-Aldrich 
(Hexane-1,6-bis(trimethylammoniumbromide)N,N,N,N’,N’,N’-
Hexamethylhexamethylenediammonium dibromide) 
Stock solution prepared in sterile water, further dilutions were done with sterile 
water 
 
Manumycin A (10 mM)                                                 Calbiochem 
Stock solution prepared in DMSO, further dilutions were done with sterile water  
  
Nicotine hydrogen tartrate salt (10 mM)           Sigma-Aldrich 
Stock solution prepared in sterile water, further dilutions were done with sterile 
water 
 
Oxotremorine sesquifumerate (10 mM) Sigma-Aldrich 
Stock solution prepared in sterile water, further dilutions were done with sterile 
water 
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PD-98059 (10 mM)                                                       Sigma-Aldrich  
(2-(2’-amino-3’-methoxyphenyl)-oxanaphthalen-4-one) 
Stock solution prepared in DMSO, further dilutions were done with serum-free 
medium for human lung fibroblast 
   
Pirenzepine (10 mM)                                        Boehringer Ingelheim 
Stock solution prepared in sterile water, further dilutions were done with sterile 
water 
 
PDGF (1 µg/ml)                                                       Sigma-Aldrich 
Stock solution prepared with 4 mM HCl in 0.1% BSA further dilutions were done 
with the serum-free medium for human lung fibroblast  
 
Pertussis Toxin (10 µg/ml) Sigma-Aldrich 
Stock solution prepared in sterile water, further dilutions were done with sterile 
water 
 
Tiotropium Bromide monohydrate (10 mM)               Boehringer Ingelheim 
Stock solution prepared in sterile water, further dilutions were performed with 
sterile water 
 
TNF alpha Human recombinant (0.1 mg/ml) Sigma-Aldrich 
Stock solution prepared in sterile water, further dilutions were done with sterile 
water 
 
Tryphostin AG1295 (5 mM)                           Sigma-Aldrich 
Stock solution prepared in DMSO, further dilutions were done with sterile water 
 
U73122 (10 mM)                                            Sigma-Aldrich 
(1-[6-[((17ß)-3-Methoxyestra-1,3,5[10]-trien-17-yl)amino]-1H-pyrrole-2,5-dione) 
Stock solution prepared in DMSO, further dilutions were done with sterile water 
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Wortmannin (10 mM)                                         Calbiochem 
Stock solution prepared in DMSO, further dilutions were done with sterile water 
 
Y27632 (10 mM)                                             Tocris 
(trans-4-[(1R)-1-Aminoethyl]-N-4-pyridinylcyclohexanecarboxamide 
dihydrocholiride) 
Stock solution prepared in 1X PBS (sterile), further dilutions were done with 
sterile water 
 
2.1.3 Buffers and Reagents for Cell Culture 
 
Culture medium for human fibroblast without FCS 
Basismedium EARLE`S MEM 
Penicillin/Streptomycin 100 U/ml / 100 µg/ml 
Non Essential Amino Acids = NEAA 1x 
Sodium Pyrovate Solution = SPS 1 mM 
 
 
Culture medium for human fibroblast with 10% FCS 
Basismedium EARLE`S MEM 
FCS 10% (v/v) 
Penicillin/Streptomycin 100 U/ml / 100 µg/ml 
Non Essential Amino Acids = NEAA 1x 
Sodium Pyrovate Solution = SPS 1 mM 
 
 
10x PBS (Phosphate buffered saline) pH 7.4-7.5 
KCl 27 mM 
KH2PO4 15 mM 
NaCl 1,38 M 
Na2HPO4 x H2O 81 mM 
Distilled water 
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1x PBS-Buffer pH 7.4-7.5 
10x PBS, 1:10 dilution with distilled water  
 
1x Trypsin-EDTA-solution 
10x Trypsin-EDTA, 1:10 dilution with1x sterile PBS-Buffer 
 
0.15% (w/v) Trypthan blue staining dye 
0.4% Trypthan Blue Stain, 3:8 dilution with 1x PBS-Buffer 
 
2.1.4 Solutions and Buffers for Proliferation Assay 
 
10% Trichloro-acetic acid 
Trichloro-acetic acide crystals 10% (w/v) 
Distilled water 
 
5% Trichloro-acetic acid 
Trichloro-acetic acide crystals 5% (w/v) 
Distilled water 
 
0,1 N Sodium hydroxide 
Sodium hydroxide pellets  0.1N 
Distilled water 
 
 
1 M Tris-HCl pH 7,4 
Tris-HCl 1 M 
Distilled water 
Adjust to pH 7.4 with HCl 
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2.1.5 Reagents for Protein Determination using the Lowry method 
 
BSA-Standard solution 
BSA 4 mg/ml 
0.1% Tris/Triton X100 solution 
 
1% Tris/TritonX100 solution 
1 M Tris-HCl-solution pH 7.4 100 mM 
Triton x-100 1% (v/v) 
Distilled water 
 
Reagent A’ 
Reagent S 1% (v/v) 
Starting Reagent A 99% (v/v) 
 
RIPA Lysis Buffer 
50 mM Tris-HCl pH 7.5 
150 mM NaCl 
0.5% Sodium deoxycholat 
1% Nonidet P-40 
0.1% SDS 
 
Protein Lysis Buffer with Protease and Phosphatase Inhibitors 
RIPA Lysis Buffer 
0.1 M EDTA pH 8 2 Mm 
125 µg/ml Pepstatin A 0.7 µg/ml (1 µM) 
100 mM PMSF 170 µg/ml (1 mM) 
10 µg/ml Leupeptin 0.5 µg/ml (1 µM) 
1.75 mM NaF 35 mM 
20 mM Na3VO4 1 mM  
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2.1.6 Primers for Polymerase Chain Reaction 
The PCR for ß actin were done using the oligonucleotide pair of   rßactin-s 
(Sigma-Aldrich) and hßactin-as (MWG Biotech). All the muscarinic and nicotinic 
receptor expression PCR’s were carried out using primers provided by MWG 
Biotech. 
 
Human 
hβactin-s 5´-TTC TAC AAT GAG CTG CGT GTG GC-3´ 
 
Human  
hβactin-as 5´-CTC GTC ATA CTC CTG CTT GC-3´ 
 
Human Muscarinic Receptor primers 
hM1-s  5´-CAG GCA ACC TGC TGG TAC TC-3´ 
hM1-as 5´-CGT GCT CGG TTC TCT GTC TC-3´ 
 
hM2-s  5´-CTC CTC TAA CAA TAG CCT GG-3´ 
hM2-as 5´-GGC TCC TTC TTG TCC TTC TT-3´ 
 
hM3-s  5´-GGA CAG AGG CAG AGA CAG AA-3´ 
hM3-as 5´-GAA GGA CAG AGG TAG AGT GG-3´ 
 
hM4-s  5´-ATC GCT ATG AGA CGG TGG AA-3´  
hM4-as 5´-GTT GGA CAG GAA CTG GAT GA-3´  
 
hM5-s  5´-ACC ACA ATG CAA CCA CCG TC-3´ 
hM5-as 5´-ACA GCG CAA GCA GGA TCT GA-3´ 
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Human Nicotinic Receptor primers 
α1-hnACHR-s       5’-CAT CAA GTA CAT CGC AGA GA-3’ 
α1-hnACHR-as     5’-TTC TCT GCT CTG GTA GGT TC-3’ 
 
α3-hnACHR-s       5’-AGG CCA ACA AGC AAC GAG-3’ 
α3-hnACHR-as     5’-TTG CAG AAA CAA TCC TGC TG-3’ 
 
α5-hnACHR-s       5’-TCA ACA CAT AAT GCC ATG GC-3’ 
α5-hnACHR-as     5’-CCT CAC GGA CAT CAT TTT CC-3’ 
 
α7-hnACHR-s       5’-CTT CAC CAT CAT CTG CAC CAT C-3’ 
α7-hnACHR-as     5’-GGT ACG GAT GTG CCA AGG ATA T-3’ 
 
α9-hnACHR-s       5’-ATC CTG AAA TAC ATG TCC AGC G-3’ 
α9-hnACHR-as     5’-AAT CGG TCT ATG ACT TTC GCC-3’ 
 
ß1-hnACHR-s       5’-TGT ACC TGC GTC TAA AAA GG-3’ 
ß1-hnACHR-as     5’-TCA ACC CTC CAG TCT TC-3’ 
 
ß4-hnACHR-s       5’-TGT GAG CAT TGG CCA TCA AC-3’ 
ß4-hnACHR-as     5’-AAT GCC AAG CCT CTG AGC TG-3’ 
 
 
2.1.7 Buffers and Solutions for RT/PCR 
DEPC-Water 
DEPC 0.2% (v/v) 
Sterile water 
 
38 
Oligonucleotide Primers 
The oligonucleotide primer stocks were prepared with DEPC water to 100 µM 
and further diluted in a 1:10 concentration with DEPC water to get a working 10 
µM concentration 
 
Gelelectrophoresis 
 
5x TBE-Buffer 
Tris 0.45 M 
Boric acid 0.44 M 
EDTA 0.012 M 
Distilled water 
 
Agarose-Gel 1.2% 
Agarose 1.2% 
0.5x TBE-Buffer 
Ethidium bromide solution (10 mg/ml)  5 µl 
 
Ethidiumbromide-solution 1% 
Ethidiumbromide 1% 
Distilled water 
 
PCR loading Buffer 
Ficoll 400 15% (w/v) 
1% Bromophenolblue-solution 0.25% (w/v) 
5x TBE-Buffer 0.5x 
Distilled water  
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2.1.8 Human Lung Fibroblast Cells 
MRC-5 
 MRC-5 human lung fibroblast cell line was developed from the lung of a 14 week 
old human fetus. The cumulative population doublings to senescence is 42-46.  
American Type Culture Collection number CCL-171. 
 
Primary Human Lung Fibroblasts 
Primary human lung fibroblasts (phLFb) were established from histologically 
normal areas of surgically resected lung tissue, which was obtained from lung 
cancer patients after thoracotomy. The protocol for obtaining human tissue was 
approved by the local ethics review board for human studies (Ethics Committee, 
Medical Faculty, University of Bonn, Bonn, Germany), and informed consent was 
obtained from the patient. 
 Primary human lung fibroblast cultures (phLFbOH.1, phLFb.4, phLFb.5, 
phLFb.6, phLFb.8, phLFb.9, phLFb.11, phLFb.12) were similarly established from 
histologically normal areas of surgically resected lung tissue from lung cancer 
patients wherein, phLFb.4, phLFb.6, phLFb.8, phLFb.11, phLFb.12 were from the 
central and phLFb.5, phLFb.9 were from the peripheral region of the lung.  
 
2.1.9 Buffers and Reagents for Protein Gel Electrophoresis and Immunoblot 
 
NuPAGE MOPS SDS Running Buffer 1X 
NuPAGE MOPS SDS Running Buffer 20X 5% (v/v) 
Distilled water  
 
Laemmli (Running) Buffer 5X 
Tris                                                     125 mM 
Glycine                                                                   7.2% 
SDS                                                                      5% 
Distilled water  
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Transfer Buffer  
Tris                                                                  25 mM 
Glycine                                                    192 mM 
Methanol                                                                 20% (v/v) 
Distilled water  
 
Ponceau S solution 
Ponceau S                                                           0.2% (w/v) 
Tris-HCl                                                             3% (w/v) 
Distilled water  
 
Tris Buffered Saline (TBS) solution pH 7.5 
Tris                                                                 50 Mm 
NaCl                                                                    150 mM 
Distilled water  
 
TBST (TBS + Tween 20) 
Tween 20                                                     0.1% (v/v) 
TBS  
 
5% Blocking solution 
Dried milk powder                                                5 gm 
Distilled water                                                      100 ml 
 
Chemiluminiscence solution 
Starting solution                                                       1% (v/v) 
Blotting substrate  
 
0.2% (w/v) Sodium Hydroxide solution 
NaOH                                                               0.2% (w/v) 
Distilled water 
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Developing solution  
Developing stock solution                                             20% (v/v) 
Distilled water  
 
Fixing solution 
Fixing stock solution                                                          20% (v/v) 
Distilled water 
 
2.1.10 Antibodies 
Anti-mAChR M2 (H-170)           Santa Cruz Biotechnology 
Anti-mAChR M3 (H-210)                         Santa Cruz Biotechnology   
Anti-Phospho-p44/42 Cell Signaling Technology 
Anti-ERK-2 IgG Santa Cruz Biotechnology 
 
2.1.11 Reagents and Solutions for Caspase-3 Fluorimetric Assay 
Caspase-3 Fluorimetric Assay was performed using the kit provided by Sigma-
Aldrich, all reagent stocks and working solutions were prepared as per the 
manufacturer’s instructions with the materials provided along with the kit unless 
otherwise specified.  
 
5X Lysis Buffer                   
HEPES 250 mM 
 (4-(2-hydroxyethyl)-1-piperazineethanesulphonicacid)   
CHAPS  25 mM 
 (3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulphonate) 
DTT  25 mM 
((D, L)-1, 4-Dithiothreitol)  
pH adjusted to 7.4 
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10X Assay Buffer 
HEPES  200 mM 
CHAPS  1% 
DTT  50 mM 
Ethylenediaminetetraacetic acid (EDTA)  20 mM 
pH adjusted to 7.4 
 
1X Assay Buffer 
10X Assay Buffer, 1:10 dilution with 17 megohm water 
 
1X Lysis Buffer 
5X Lysis Buffer, 1:5 dilution with 17 megohm water 
 
1X Lysis Buffer with Protease Inhibitors 
0.1 M EDTA pH 8  2 mM 
125 µg/ml Pepstatin A  0.7 µg/ml 
200 µg/ml Aprotinin  2 µg/ml 
Volume made up with 1X Lysis Buffer   
 
Caspase-3 Substrate Solution  10 mM 
Caspase-3 Substrate (Ac-DEVD-AMC)  2.5 mg 
DMSO  370 µl 
 
 
Caspase-3 Inhibitor Solution   2 Mm 
Caspase-3 Inhibitor (Ac-DEVD-CHO)  0.5 mg 
DMSO  500 µl 
 
Caspase-3 Inhibitor Assay solution  200 µM 
Caspase-3 Inhibitor Solution, 1:10 dilution with 1X Assay Buffer 
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Caspase-3 Positive Control Solution  100 µg/ml 
Caspase-3 Positive Control   5 µg 
17 Megohm Water  50 µl 
 
Caspase-3 Positive Control Assay Solution  1 µg/ml 
Caspase-3 Positive Control Solution, 1:100 dilution with 1X Assay Buffer 
 
Reaction Mixture, 400 µl per reaction for 96 well plate assay 
10 mM AC-DEVD-AMC  12.5 µl 
1X Assay Buffer  7.5 ml  
 
7-Amino-4-methylcoumarin (AMC) Standard Solution  10 mM 
AMC  1 mg 
DMSO  0.57 ml 
 
2.1.12 Equipment  
Mycycler Thermal Cycler System Bio-Rad 
Photometer DU-64 spectrophotometer 
Liquid Scintillation Analyzer  Tri-Carb2100 TR, Packard 
Fluorescence Microplate Reader Fluorometer Fluostar OPTIMA, BMG 
 
 
2.1.13 Tools for Statistical Analysis 
GraphPad Software 
GraphPad InSat 3.01 program was used to calculate statistical significance of 
differences using ANOVA, followed by Dunnet’s or Bonferroni’s test. All values 
are mean±SEM of n experiments. A P value of < 0.05 was accepted as 
significant. All graphical representations were generated using the GraphPad 
Prism software. 
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Microsoft Excel 5.0 and Excel 97 
This program was used for calculation of means and SEM’s from individual 
experimental data and summarizing these values for a particular set.   
 
RFLPscan 2.01 
Optical density of bands from PCR and western blot experiments were 
semiqauntitatively measured using the RFLPscan software. 
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2.2 Methods 
2.2.1 Culture of Human Lung Fibroblast 
The MRC-5 cell line was derived from normal lung tissue of a 14-week-old male 
fetus (189). Cryogenically preserved MRC-5 human lung fibroblast culture was 
thawed for 1 minute at room temperature followed by thawing at 37°C on a water 
bath. The contents of the vial were then transferred to 75 cm2 pre-incubated 
culture flask containing human fibroblast medium supplemented with 10% FCS in 
a humidified incubator at 37oC and 5% CO2. After 24 hours of incubation the 
medium was changed to remove the cryoprotective agent DMSO, to prevent cell 
damage. The cells were then allowed to grow, with the medium being changed 
twice per week. Upon confluence cells were passaged further. 
For this purpose the cells were washed with warm sterile 1X PBS followed by 
addition of  warm sterile 1X Trypsin/EDTA solution   just enough to cover the cell 
surface to facilitate the detachment of the cell from the surface of the flask. 
Trypsin is a proteolytic enzyme which helps in breaking cell-cell adhesion 
whereas EDTA is a chelator that binds divalent cations such as calcium and 
magnesium present between the cells allowing trypsin access to the cell-cell and 
cell-substrate bonds. The cells were incubated for 45 seconds after which the 
tyrpsin was aspirated out. Then the cells were re-suspended in medium with 10% 
FCS and centrifuged at 1000RMP for 5 minutes. The supernatant was discarded 
and the cell pellet was re-suspended in the 10% FCS medium. Cell count was 
carried out using trypthan blue (20µl of cell suspension plus 80µl of the stain) in a 
Neubauer counting chamber. Required amount of cells were seeded further in a 
175 cm2 culture flask with medium containing 10% FCS and an aliquot was re-
suspended in a vial containing medium with 10% FCS and 5% DMSO and frozen 
to -80oC before being stored in liquid nitrogen. 
Primary human lung fibroblasts were established from histologically normal areas 
of surgically resected lung tissue, which was obtained from lung cancer patients 
after thoracotomy. Tissue was sliced into tiny pieces, treated with pronase 
(1mg/ml) at 37oC for 30 minutes, placed in cell culture plates, and incubated in 
human fibroblast medium with 15% FCS. After 2 weeks, fibroblasts had grown 
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out from the tissue and were passaged by standard trypsinization protocol as 
mentioned in the case of MRC-5 cells.  
 
2.2.2 RNA Preparation 
Total RNA isolation was done using RNeasy tissue kit provided by Qiagen as per 
the manufacturer’s instructions. 
The RNeasy procedure for RNA purification combines the selective binding 
properties of a silica based membrane with the speed of microspin technology. A 
specialized high salt buffer system assists the binding of RNA to the silica based 
membrane. 
Cells were seeded in a 55mm dish and grown to 85% confluence prior to being 
used for RNA isolation.  The medium was aspirated out and the cell surface was 
washed with 1X PBS followed by addition of the RLT lysis buffer (350µl). The cell 
lysate was homogenized by centrifugation with the QIA shredder for 2 minutes at 
13000 RPM and the filtrate was collected in 1.5ml Eppendorf tubes. Ethanol 
(70%) was added to the filtrate to provide appropriate binding conditions and the 
sample was then applied to an RNeasy spin column, centrifuged at 10000 RPM 
for 15 seconds. The flow-through was discarded and the spin column was placed 
on a new collection tube. The wash buffer RW1 (700µl) was added on the spin 
column and centrifuged for 15 seconds at 10000 RPM. The flow-through was 
discarded and the spin column was placed on a new collection tube. The 
muscarinic receptor genes are intronless, and contamination of RNA preparation 
by genomic DNA would cause false-positive PCR results; hence an additional 
DNase treatment step was carried out by adding 80µl DNase (10µl DNase + 70µl 
RDD buffer) on the spin column and incubating it at room temperature for 15 
minutes. After incubation, the spin column was centrifuged and the flow-through 
discarded. Buffer RPE was added on the spin column and centrifuged at 10000 
RPM for 15 seconds.  The RPE buffer wash step was repeated with an extended 
centrifugation time for 2 minutes. The flow-through was discarded and the 
RNeasy column was spun dry at 10000 RPM for 15 seconds.  The elution was 
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done using 40µl of RNase free water at 10000 RPM for 15 seconds twice to get a 
total volume of 80µl of eluate collected into a sterile tube.  
The RNA concentration in the sample was measured photometrically at a 
wavelength of 260nm in a 1:40 dilution with RNase free water and the sample 
preparation was stored at -80oC.  
Note: - All the steps involved in this protocol were performed in RNase free 
conditions using RNase free pipette tips to prevent degradation of the sample.  
 
2.2.3 Reverse Transcription 
Reverse transcription also known as “first strand reaction,” is a process wherein 
complementary DNA (cDNA) is made from an mRNA template using dNTP’s and 
an enzyme called reverse transcriptase.  
RNA is susceptible to degradation hence care was taken to prevent any 
contamination by using RNase free pipette tips and all reactions were carried out 
on ice. Total RNA concentration was calculated and amount equivalent to 1µg of 
RNA was used as a starting template, making up the volume to 12.5µl with 
DEPC water. The RT-Master mix containing oligodT primer in a reverse 
transcriptase buffer was added to this probe making up the volume to 20µl/probe 
and incubated at 37oC for 1 hr. The reverse transcription was terminated by 
incubation at 93oC for 5 minutes. Following which the probes were centrifuged 
and 80µl of sterile water were added per probe. The synthesized cDNA were 
stored at -20oC or 5µl of this cDNA was used as template for further PCR 
reactions.  
 
 
A260 nm x 40 x Dilution Factor = RNA concentration in µg/ml 
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RT-Master-Mix 
 
 
Reagents                                                                                  Quantity per probe 
 
10 µM Oligo dT-Primer       2 µl   
5 mM dNTP-Mix        2 µl 
10x RT-Buffer        2 µl 
10 U/µl RNase Inhibitor RNasin Plus 
(1:4 dilution with 1x RT-Buffer)       0.5 µl 
Omniscript Reverse Transcriptase      1 µl 
Total volume                                                                                         7.5µl 
 
2.2.4 Polymerase Chain Reaction (PCR) 
The polymerase chain reaction (PCR) is a technique for "amplifying" a specific 
DNA sequence. 
To beware of any contamination all the apparatus used was autoclaved and 
sterile pipette tips were used. For the PCR 5µl of cDNA was used as the 
template mixed with the PCR-Master mix and run on a PCR thermal cycler set to 
the following parameters; 
 
Function                                Temperature                                Time  
Initial Denaturation   94°C                          3 mins  
23 -35 Cycles of:- 
-Denaturation             94°C                 45 s 
-Annealing                 53°C to 60°C                          30 s 
-Elongation              72°C                 1 min 
 
Final Elongation   72°C                10 mins one time  
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PCR-Master-Mix 
Reagents                                                                                 Quantity per probe 
Water                                                                                                  32.5µl 
10X PCR Reaction Buffer       5 µl 
50 mM MgCl2        1,5 µl 
10 mM Desoxynucleotide-Mix      1 µl 
10µM sense-Primer                                                                             2.5µl 
10µM antisense-Primer                                                                       2.5µl                                         
5 U/µl TaqDNA Polymerase      0,5 µl 
Total volume                                                                                        45µl 
 
2.2.5 Agarose Gel-Electrophoresis 
At the end of the PCR reaction 5µl of a PCR buffer was added per probe and 
mixed well with a pipette. For the purpose of electrophoresis, a 1.2% agrose gel 
was used and 30µl per probe was loaded onto the gel and run at a constant 
current of 72 mA for 1 hour. A 100bp DNA ladder was also loaded onto the gel as 
a marker. Then the gel was placed under UV light; causing the ethidium bromide 
intercalated into the DNA to fluoresce. Gel photos were taken using a digital 
camera. Optical density of bands was quantified by RFLPscan software, 
corrected for ß-actin, and referred to the respective amplification of genomic DNA 
to normalize for variations in PCR effectiveness.    
 
2.2.6 DNA Preparation 
Genomic DNA from MRC-5 cell line was used as a positive control for the 
receptor expression studies carried out on human lung fibroblasts using 
polymerase chain reaction. The genomic DNA for this purpose was isolated 
using the DNeasy tissue kit provided by Qiagen as per the manufacturer’s 
instructions. The basic principle involved here, is that the cells are lysed with 
Proteinase K which inactivates the DNases with the buffering conditions being 
adjusted to provide optimal DNA binding conditions when the lysate is loaded 
onto the DNeasy Mini spin column.  
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Cells in culture medium were centrifuged at 1750RPM for 5 minutes; the pellet 
was resuspended in 200µl of 1XPBS, 20µl of Proteinase K and 200µl Buffer AL. 
The reaction tube was mixed thoroughly by vortexing and then incubated at 70oC 
for 10 minutes. Ethanol 200µl (96%) was added to the sample and homogenized 
by vortexing. The homogenized sample was then pipetted into the DNeasy spin 
column placed in a 2ml collection tube and centrifuged at 800RPM for 1 minute. 
The flow-through was discarded and the spin column was placed on a new 
collection tube. Buffer AW1 (500 µl) was added and the tube was centrifuged at 
800RPM for 1 minute. Then another wash step with Buffer AW2 was carried out 
at 14000RPM for 3 minutes to dry the DNeasy membrane. The DNeasy spin 
column was thereafter placed on a new 1.5ml microcentrifuge tube and 200µl of 
Buffer AE was added directly onto the DNeasy membrane, incubated for 1 
minute at room temperature, and centrifuged at 8000RPM for 1 minute to elute.  
The DNA concentration was measured photometrically at 260nm. 
 
2.2.7 Protein Preparation 
Cells were seeded in 55mm culture dishes and grown in a humidified incubator at 
37oC and 5% CO2 with the last 24 hours under serum free conditions. Upon 
reaching 80-85% confluence the medium was aspirated out. The cells were then 
washed with 1XPBS (cold) and cellular proteins were extracted using 150-300µl 
(per dish) of the RIPA buffer (50mM Tris-HCl [pH 7.5], 150 mM NaCl, 0.5% 
sodium deoxycholat, 1% Nonidet P-40, 0-1% [wt/vol] SDS, 2mM EDTA [Ph 8.0]) 
containing protease inhibitors PMSF (1 mM), pepstatin A (0.7 µg/ml), leupeptin 
(0.5 µg/ml) and phosphatase inhibitors sodium fluoride (35 mM) and sodium 
orthovandate (1 mM). Phosphatase inhibitors were added to lysis buffer in the 
case of protein extracts being immunoblotted to test for activated phospho-
proteins. The cell suspension was then transferred to a sterile 1.5ml 
microcentrifuge tube and centrifuged at 14000RPM at 4oC for 15 minutes; the 
supernatant was used for total protein determination. Care was taken to perform 
all the above mentioned steps on ice to prevent sample degradation.   
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2.2.8 Protein Determination  
Protein determination was carried out using the Protein Assay kit which is a 
colorimetric assay for protein concentration following detergent solubilization 
based on the reaction of protein with an alkaline copper tartrate solution, and the 
subsequent reduction of the Folin reagent by the copper treated protein giving 
rise to a characteristic blue colour which can be detected colorimetrically by 
absorbance at 750 nm.  
 For the assay 5 µl of the supernatant previously extracted was mixed with 45 µl 
of 0.1% Tris-Triton-X 100. Then 100µl of Working Reagent A’ was added to the 
probe followed by 800 µl of Reagent B. Similarly 50 µl BSA standards in the 
concentrations of 50, 100, 300, 700, 1100 and 1500 µg/ml in    0.1% Tris-Triton-
X100 were mixed with 100 µl of Working Reagent A’ and 800 µl of Reagent B 
was added to each probe. For the blank reading 5 µl of the lysis buffer was 
treated in a similar fashion. The probes were later vortexed and incubated at 
room temperature for 15 minutes. The absorbance was measured 
spectrophotometrically at 750 nm, and a regression analysis was then performed 
with the help of the absorbance values obtained for the standards to calculate the 
concentration for the sample probe. 
 
2.2.9 Protein Gel-Electrophoresis and Immunoblot 
Protein gel electrophoresis was performed using the Novex Mini Cell along with 
the X Cell Sure Lock while the immunoblot was done using X Cell II Blot Module. 
The equipments required were provided by Invitrogen and experiments were 
perfomed as per the manufacturer’s instructions. 
 
2.2.9.1 Protein Gel-Electrophoresis 
The electrophoretic separation of proteins is based on the principle of the sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) wherein the 
proteins are separated on the basis of their molecular weight. SDS is an anionic 
detergent which denatures secondary and non disulphide linked tertiary 
structures of the proteins, and applies a negative charge to each protein in 
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proportion to its mass enabling them to migrate towards the positive pole when 
run through a polyacyrlamide gel placed in an electric field. 
Cellular proteins were extracted in RIPA buffer as previously described in 3.17. 
Totals of 50-100µg protein equivalents for receptor expression studies or 20-
50µg protein equivalents for MAPK activation studies were mixed with Roti-Load 
1, a reducing protein loading buffer and heated at 70oC for 10 minutes which 
further denatures the proteins by reducing the disulphide linkages, thus 
overcoming some forms of tertiary protein folding, and breaking up quaternary 
protein structure. The XCell II mini cell apparatus was set up as per instructions 
and 500 µl of anti oxidant was added to the running buffer in the upper chamber 
which helps keep the sample reduced while the gel runs. Kaleidoscope marker 
proteins (5µl) were loaded as molecular size standards and the gel run was 
carried out at 200 V constant at approximately 80-90 mA current for 90 minutes.  
For the muscarinic receptor expression studies the samples were separated on 
10% acrylamide Tris glycine precast gels (Mirador, Montreal, PQ, Canada) using 
the Laemmli buffer system (5% SDS, 125 mM Tris, 7.2% glycine whereas, a 4-
12% Nu PAGE Bis-Tris Gel using the 1X MOPS-SDS buffer system was utilized 
for cell signaling studies.  
 
2.2.9.2 Immunoblot 
Prior to the completion of the gel run, equilibration of the polyvinylidine difluoride 
(PVDF) membrane was done by soaking it in methanol for 30 seconds followed 
by washing with distilled water for 1-2 minutes and 20 minutes in transfer buffer. 
Filter paper and blotting pads were pre soaked in transfer buffer prior to being 
used. After the completion of the gel run, the gel was removed from the gel 
cassette and equilibrated in transfer buffer for 10-15 minutes. At the end of the 
equilibration period a sandwich assembly of the membrane, gel, filter paper and 
blotting pads was prepared and transferred to the X Cell II Blot Module apparatus 
as instructed in the manual. The inner and outer chambers were then filled with 
transfer buffer and the unit was run at a constant current of 250 mA (100 V) for 
90 minutes. 
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Once the blotting step was over the PVDF membrane was transferred onto a tray 
on a rocker and stained using Ponceau S (0.2% w/v) to ensure the quality of the 
blot and the lanes were marked. After the lanes were marked the stain was 
removed by washing twice with water followed by a TBS wash step for 3 minutes. 
The membrane was then blocked using 10 ml of 5% blocking solution (dried milk 
powder in 0.05% TBT) overnight at 4oC.  
The blocking solution was then discarded and 10 ml of the primary antibody 
solution prepared in 3% blocking solution to appropriate dilution was added onto 
the membrane and left to incubate for 90 minutes at room temperature on the 
rocker. The membrane was then washed thrice for 10 minutes with 0.1% TBST 
and blocked with 3% blocking solution twice for 10 minutes. This was followed by 
addition of 10 ml of secondary antibody linked with a reporter enzyme diluted to 
optimal concentration in a 3% blocking solution over the membrane and 
incubated for 45 minutes on a rocking platform. After the end of the incubation 
period with the secondary antibody the membrane was washed for 15 minutes 
four times with 0.1% TBST. 
During the time of final wash steps of the protocol the chemiluminescene 
detection solution was prepared employing BM chemoluminescence blotting 
substrate peroxidase (POD) kit and kept at room temperature. At the end of the 
final wash step the membrane was taken to the photo laboratory. The excess 
buffer from the washed membrane was drained and it was placed on a piece of 
two fold transparent film (protein side up). Then the detection solution was added 
on the protein side of the membrane for 1 minute following which a sandwich was 
prepared of the membrane with a new plastic wrap by closing the membrane with 
the second fold of the film. Care was taken to remove any trapped air bubbles by 
gently pressing the membrane wrap sandwich. The membrane wrap sandwich 
was then transferred to an autoradiographic cassette and exposed to an X-ray 
film for anywhere between 15 seconds to 5 minutes depending on the intensity of 
the signal. The film was then placed in a developing solution for 3-5 minutes, 
washed in water for 3 minutes and finally in a fixing solution for 5 minutes. Based 
on the intensity of the signal a second film was developed to optimal exposure 
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time. The developed films were then scanned and RFLPscan software was 
employed to quantify the optical density of the protein bands.  
 
2.2.9.3 Membrane Stripping 
Stripping of the membrane was done to make sure the loading of the samples 
were consistent by re-probing the membrane with another antibody. For this 
purpose the membrane was soaked in methanol and washed with distilled water. 
Then 0.2% NaOH solution was added onto the membrane for 5 minutes over a 
rocking platform followed by washing the membrane for 5 minutes with distilled 
water. Finally the membrane was blocked with a 5% blocking solution overnight 
at 4oC. This was followed by the addition of another primary antibody in a 3% 
blocking solution and the remaining protocol for the immunoblotting was similar 
to as described previously. 
  
2.2.10 (3H)-Thymidine Incorporation Proliferation Assay 
Human lung fibroblasts cells were cultured as previously described in 3.11. Cells 
were then trypsinized, harvested, and seeded into 12-well dishes at a density of 
7.5 x 104 or 1.5 x 105  cells per well depending on the protocol being 
implemented. Four different sets of protocols were tested to find conditions under 
which cholinergic effects might be particularly prominent. In the first set, cells 
were initially cultured for 24 hours in the presence of 10% FCS, followed by an 
additional 48 hours under FCS-free conditions. Test drugs were either added at 
the onset of the FCS-free period or 24 hours later. (3H)-Thymidine (37kBq) was 
present during the last 24 hours of the 3-d culture period. In another series of 
experiments, fibroblasts were cultured for 30 or 48 hours under FCS-free 
conditions from the onset. Test drugs were present from the beginning, and (3H)-
Thymidine during the last 24 hours. In experiments of 48 hour duration or longer, 
medium was renewed after 24 hours to ensure the presence of active drugs 
during the entire culture period. After the end of the incubation period the cells 
were washed with ice-cold 1X PBS, followed by a denaturation in 10% 
trichloroacetic acid (TCA) for 10 minutes at 37oC. The TCA was then aspirated 
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out and the cells were washed once again with ice cold 1X PBS and DNA was 
extracted during incubation for 1 hour in 0.1mol/l NaOH at 37oC.   Samples of the 
supernatant solution (300 µl portions) were neutralized with 200 µl of Tris HCl 
(pH 7.4), combined with the scintillation cocktail, and the radioactivity was 
measured by liquid scintillation spectrometry in a Packard 2100 liquid scintillation 
analyzer. A blank reading was also perfomed correct for counting efficiency. In a 
further set of experiments cells were FCS-deprived and drugs were applied from 
the onset of the test culture period and the cells were incubated for 6 hours prior 
to the addition of (3H)-Thymidine, for a total of 30 hours. At the end of the 
incubation period the cells were washed with ice-cold PBS and denatured with 
5% TCA as mentioned before and DNA was extracted by incubating the cells 
with 0.1mol/l NaOH at 4oC overnight. The radioactivity was them determined as 
described above. These conditions were held for subsequent experiments with 
subtype preferring muscarinic receptor anatagonist and for elucidating the 
intracellular signaling pathways.  
 
2.2.11 Caspase- 3 Fluorimetric Assay 
The assay was performed using the Caspase-3 Fluorimetric Kit provided by 
SIGMA as per the manufacturer’s instructions. 
Caspase-3 is an intracellular cysteine protease that exists as a proenzyme, 
becoming activated during the sequence of events associated with apoptosis. 
The caspase-3 fluorimetric assay is based on the hydrolysis of the peptide 
substrate acetyl-Asp-Glu-Val-Asp-7-amido-4-methylcoumarin (Ac-DEVD-AMC) 
by caspase-3, resulting in the release of the fluorescent 7-amino-4-
methylcoumarin (AMC) moiety which when excited by light at 360 nm wavelength 
emits fluorescence at 460nm wavelength. The level of caspase enzymatic activity 
in the cell lysate being directly proportional to the fluorescence signal detected 
with the fluorescent microplate reader. 
Stock solutions were prepared and diluted for assay use as per the instructions 
provided.  Cells were seeded into a 24-well dish at density of 4 x 104   cells per 
well in the presence of 10% FCS in a humidified incubator at 37oC and 5% CO2. 
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Upon reaching 80-85% confluence the medium was aspirated out and the cells 
were treated with various apoptosis inducers in the presence or absence of a 
muscarinic agonist under serum free conditions and incubated a further 4 hours. 
At the end of the incubation period the plate was kept on ice and the medium 
aspirated out, following which 50 µl of 1X Lysis Buffer was added onto each well 
and the plate was left to incubate on ice for 15-20 minutes. Then 400 µl of 1X 
Assay Buffer containing the substrate was added to each well and mixed well by 
pipetting.  Readings were calculated in duplicates for each well by transferring 
200 µl to a fluorimeter multi well plate. Two wells for substrate blank, two for 
caspase positive control and two for caspase positive in combination with the 
caspase inhibitor were also prepared. Parallelly an AMC standard curve analysis 
was performed over a concentration range 0.02, 0.1, 0.2, 0.4 and 0.8 nM of AMC 
in 200 µl of 1X Assay Buffer. The fluorescence was read in a kinetic mode every 
10 minutes over a period of 1 hour using FLUOstar OPTIMA (BMG LABTECH) 
microplate reader set to optimal parameters. The enzyme activity was calculated 
using the AMC standard curve.  
 
AMC Standard Curve  
AMC Solution Nmol AMC 
in200µl 
AMC Working 
Solution (10µM)   
1X Assay Buffer 
100 nM 0.02 3 µl 297 µl 
500 nM 0.1 15 µl 287 µl 
1 µM 0.2 30 µl 270 µl 
2 µM 0.4 60 µl 240 µl 
4 µM 0.8 120 µl 180 µl 
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Representation of the Pipetting Scheme followed for the Caspase-3 Assay 
Sample Apoptosis 
Inducers 
Muscarinic  
Agonist 
Caspase  
Inhibitor 
Caspase 
positive  
Blank     
1 Ii + Iiii    
2 Ii + Iiii  +  
3 Iii + Iiii    
4 Iii + Iiii  +  
5  C   
6 Ii + Iiii C   
7 Ii + Iiii C +  
8 Iii + Iiii C   
9 Iii + Iiii C +  
10    + 
11   + + 
Actinomycin D 200 ng/ml (Ii), Cycloheximide 10 µg/ml (Iii) , TNF alpha H 10 ng/ml 
(Iiii) , Carbachol 10µM (C), Caspase-3 positive control 0.05 µg/ml, Caspase-3 
inhibitor 2 µM,  
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3. Results 
3.1 Muscarnic Receptor Expression in Human Lung Fibroblasts 
3.1.1 Muscarinic Receptor Expression in MRC-5 Human Lung Fibroblasts 
Semi-quantitative RT-PCR’s were performed to determine the expression pattern 
of the mRNA encoding for the different muscarinic receptors subtypes in MRC-5 
fibroblast cell line. Total RNA was isolated as described previously in 3.12 and 
first-strand cDNA was synthesized using Omniscript reverse transcriptase. Then 
the PCR amplification was carried out using specific oligonucleotide primers for 
human muscarinic receptors (M1-M5) or ß-actin in a programmable thermal cycler 
set to 23 cycles for ß-actin and 35 cycles for muscarinic receptors.   
Positive controls were performed for every PCR using genomic DNA (gDNA) 
isolated for MRC-5 cells and one PCR lacking template DNA was regularly 
performed as a negative control. Table A, shows the PCR product size and the 
specific annealing temperature for the primers pairs employed. 
As shown in Figure 1, MRC-5 fibroblasts express mRNA encoding different 
muscarinic receptor subtypes. The most prominent expression was found for 
mRNA encoding M2 receptor, followed by M3 receptor transcripts. Lower but still 
detectable expression for M4 receptor was observed, while only traces of M5 
receptor encoding mRNA were detected, and no transcript for M1 receptor was 
detected. The expression pattern for the mRNA encoding the muscarinic 
receptors was found to be consistent under the culture conditions, as a similar 
pattern was found in different passages (passages 1-13). 
Western blot analysis using specific commercially available polyclonal antibodies 
for M2 and M3 receptors were performed which confirmed the expression of the 
M2 and M3 receptors at protein levels (Figure 1.C). A single band somewhat 
larger than 80 kDa was observed for the immunoblot for M2 receptor. A band of 
similar size was also observed for the M3 receptor, but here two additional 
products, with a lower molecular weight, were also detected. These probably 
reflect the cellular degradation products which are still recognized by the 
antibody. An immunoblot performed with proteins extracted from rat lung tissue is 
also shown in Figure 2 for comparison purposes. 
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Table A 
Receptor Primer pair Product size (bp) Annealing 
temperature oC 
hM1 hM1-s/hM1-as 538 58 
hM2 hM2-s/hM2-as 654 53 
hM3 hM3-s/hM3-as 560 60 
hM4 hM4-s/hM4-as 498 58 
hM5 hM5-s/hM5-as 751 57 
 
 
Figure 1. Expression of human muscarinic receptors (M1-M5) in MRC-5 Human Lung 
Fibroblasts. 
A. Samples of RT-PCRs of human muscarinic receptors (M1-M5) on RNA isolated from MRC-5 
human lung fibroblasts. Cells were grown in 55-mm culture dishes to confluence, total RNA was 
isolated, treated with DNase, and used for RT-PCR with primers specific for the human 
muscarinic receptors or ß-actin. To control effectiveness of primer pairs, PCRs were also 
performed on genomic DNA (gDNA) isolated from MRC-5 cells. One PCR lacking template DNA 
was regularly performed to account for any contamination (negative control, -Ctr.). PCR products 
were separated on a 1.2% agarose gel. 
B. Densitometric evaluation of a series of experiments. Given are mean values (+SEM) of three 
experiments performed with cells of passages 1-13. Values were normalized first for ß-actin to 
correct for quality of cDNA preparation and second for the respective amplification products 
obtained on gDNA to correct for effectiveness of the respective primer pairs. 
C. Immunoblot analysis of protein extracts of MRC-5 cells for comparison of rat lung tissue sing 
commercially available antibodies against M2 and M3 receptor protein. Given are the 
representative samples of SDS-PAGE. 
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3.1.2 Muscarinic Receptor Expression in Primary Human Lung Fibroblasts 
Primary human lung fibroblasts cultures (phLFb) were obtained from patients 
with lung cancer and total RNA was isolated, followed by the first-strand DNA 
synthesis and amplification using PCR as described previously. As shown in 
Figure 2, mRNA encoding muscarinic receptors was detected. The expression of 
mRNA encoding the M2 receptor transcript was most dominant, followed by 
mRNA encoding M1 and M3 receptors, whereas only traces of mRNA for M4, and 
none for M5, were observed at different passages. 
To explore the regional expression pattern of mRNA encoding for muscarinic 
receptors M2 and M3 a wider pool of primary human lung fibroblasts cultures was 
obtained from lung cancer patients wherein, c/phLFb.4, c/phLFb.6, c/phLFb.8, 
c/phLFb.11, c/phLFb.12 were from the central and p/phLFb.5, p/phLFb.9 were 
from the peripheral region of the lung was obtained. Total RNA was isolated, 
followed by the first-strand-DNA synthesis and amplification using PCR as 
described previously. As Figure 2C shows, mRNA encoding muscarinic receptors 
M2 and M3 were detected, consistent with the results depicted in Figure 2A+B 
implicating that; there was no significant difference in the expression pattern of 
mRNA encoding for M2 and M3 muscarinic receptors in primary human lung 
fibroblast from different regions of the lung. 
 
Figure 2. Muscarinic receptor expression in Primary Human Lung Fibroblasts 
A. Samples of RT-PCRs of the five human muscarinic receptors (M1-M5) on RNA isolated from 
primary human lung fibroblasts (phLFb). Cells were grown in 55-mm culture dishes to confluence, 
total RNA was isolated, treated with DNase, and used for RT-PCR with primers specific for the 
human muscarinic receptors or ß-actin. To control effectiveness of primer pairs, PCRs were also 
performed on genomic DNA (gDNA) isolated from MRC-5 cells. One PCR lacking template DNA 
was regularly performed to account for any contamination (negative control, -Ctr.). PCR products 
were separated on a 1.2% agarose gel. 
B. Densitometric evaluation of a series of experiments. Data are means (+SEM) of three 
experiments performed on cells of passages 1, 5, and 10. Values were normalized first for ß-actin 
to correct for quality of cDNA preparation and second for the respective amplification products 
obtained on gDNA to correct for effectiveness of the respective primer pairs. 
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C. Samples of RT-PCRs of human muscarinic receptors (M1 and M2) on RNA isolated from 
primary human lung fibroblasts obtained from different regions of the lung. Cells were grown in 
55-mm culture dishes to confluence, total RNA was isolated, treated with DNase, and used for 
RT-PCR with primers specific for the human muscarinic receptors or ß-actin. To control 
effectiveness of primer pairs, PCR were also performed on genomic DNA (gDNA) isolated from 
MRC-5 cells. One PCR lacking template DNA was regularly performed to account for any 
contamination. PCR products were separated on a 1.2% agarose gel. 
D. Densitometric evaluation of a series of experiments. Data are means (+SEM) of three 
experiments performed of passages 0, 1, and 2. Values were normalized for ß-actin to correct for 
quality of cDNA preparation and second for the respective amplification products obtained on 
gDNA to correct for effectiveness of the respective primer pairs. 
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Figure 2. 
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3.2 Muscarinic Stimulation of Proliferation of Human Lung Fibroblasts 
3.2.1 Muscarinic Stimulation of Proliferation of MRC-5 Human Lung 
Fibroblasts 
Various experimental conditions were tested in order to determine optimal 
parameters for the (3H)-thymidine incorporation assay. The purpose being to test 
whether putative muscarinic effects on fibroblast proliferation were dependant on 
culture conditions and exposure time. In the first set of experiments, cells were 
cultured for 24 hours in the presence of 10% FCS, followed by 24 hours under 
FCS-free conditions in the presence of (3H)-thymidine and in the absence or 
presence of increasing concentrations of carbachol. Under control conditions 
(absence of drugs), (3H)-thymidine incorporation amounted to 7.281 ± 548 d.p.m 
(disintegration per minute) (n=52). Carbachol induced an increase in (3H)-
thymidine incorporation by 38 ± 18% at 10 µM in a concentration-dependent 
manner (Figure 3A). As shown in Figure 3A, this effect was abolished in the 
presence of 1 µM atropine which alone did not have an effect on (3H)-thymidine 
incorporation. In spite of the fact that the stimulatory effect of carbachol was 
clearly significant, the magnitude of the effect showed considerable variation. 
In a second set of experiments, cells were again cultured for 24 hours in the 
presence of 10% FCS, followed by 48 hours FCS-free conditions in the absence 
or presence of carbachol (10 µM) with (3H)-thymidine present for the last 24 h. 
Under these conditions, carbachol caused an increase in (3H)-thymidine 
incorporation by 52 ± 10% (Figure 3B). Here again the proliferative effect of 
carbachol was inhibited by atropine and also by the long-acting muscarinic 
antagonist tiotropium (Figure 3B). Furthermore, oxotremorine also caused a 
similar increase (by 61%), an effect also prevented by atropine (Figure 3B). For 
comparison, when FCS (1 or 10%) was present instead of muscarinic agonist 
during the last 48 hours, (3H)-thymidine incorporation was enhanced by 69 ± 17% 
(n = 6) and 216 ± 30% (n = 9), respectively, compared to FCS-free conditions. 
In the third protocol, cells were FCS-deprived and drugs were applied from the 
onset of the test culture period. Under these conditions, 10 µM carbachol or 
oxotremorine increased (3H)-thymidine incorporation by 64 ± 8% and 100 ± 26%, 
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respectively, when present 24 hours before (3H)-thymidine, for a total of 48 
hours. These effects were again shown to be atropine sensitive (Figure 3C).  
In a further set of experiments carbachol was applied 6 hours before (3H)-
thymidine, for a total of 30 hours, (3H)-thymidine incorporation was increased by 
76 ± 4% (n = 80). These conditions were held for the subsequent interaction 
experiments with subtype-preferring muscarinic receptor antagonists. 
As shown in Figure 4 when 1% FCS was present from the onset of the test 
culture period (6 hours before (3H)-thymidine, for a total of 30 hours), (3H)-
thymidine incorporation was increased by 450%. Additional presence of 10 µM 
carbachol or oxotremorine induced a further significant increase in (3H)-thymidine 
incorporation, by about 300% and 240% respectively, relative to the FCS-free 
controls (Figure 4). This corresponds to an increase of 54 and 43% respectively, 
when expressed in relation to FCS-containing control experiments. 
 
Figure 3. Effects of muscarinic agonists and antagonists on (3H)-thymidine incorporation 
in MRC-5 Human Lung Fibroblasts  
7.5 x 104 cells were seeded in 12 well dishes in the absence or presence of 10 % FCS as 
indicated. In each series (3H)-thymidine (37 kBq) was present for the last 24 h. 
 A. Effects of carbachol, at concentrations indicated by the abscissa, in absence (open symbols) 
or presence (filled symbols) of 1 µM atropine. Test drugs were added together with (3H)-
thymidine. 
 B and C. Carbachol (C, 10 µM), oxotremorine (O, 10 µM) and/or atropine (A, 1 µM) and/or 
tiotropium (T, 0.1 µM) were present already 24 h prior to (3H)-thymidine until the end of the 
protocol. Data are means (±SEM) of n=3-12 (mostly n≥6). ** P < 0.01; *** P< 0.001 vs. controls; + 
P < 0.05, ++ P < 0.001, +++ P < 0.001 vs. the respective value in the absence of antagonists. 
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Figure 3. 
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Figure 4. Comparison of the effects of carbachol and oxotremorine on (3H)-thymidine 
incorporation in MRC-5 human lung fibroblasts in absence and presence of FCS. 7.5 x 104 cells 
were seeded in 12 well dishes and cultured under FCS-free conditions or in the presence of 1% 
FCS. Carbachol (Carb, 10 µM) or oxotremorine (Oxo, 10 µM) was added from the onset of 
incubation for a total of 30 h, (3H)-thymidine (37 kBq) was present for the last 24 h. Data are 
means (±SEM) of n=3-12. *** P< 0.001 vs. controls (Ctr); + P < 0.01 vs. the respective value in the 
presence of FCS alone. 
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3.3 Characterization of Muscarinic Receptor Sub-Type  
3.3.1 Inhibition of Muscarnic Proliferation using Receptor Sub-Type 
Specific Antagonists in MRC-5 Human Lung Fibroblasts 
Receptor sub-type characterization studies were performed to determine the 
functional receptor/receptors involved in the muscarinic stimulation of 
proliferation in MRC-5 human lung fibroblasts using different selective muscarinic 
antagonists. As summarized in Figure 5, all muscarinic receptor antagonists 
tested inhibited the stimulatory effect of carbachol on (3H)-thymidine 
incorporation in a concentration dependent manner. Tiotropium was by far the 
most potent drug, with an IC50 value of 14 pM. The M2/M4, receptor-preferring 
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antagonists, AQ-RA 741, AF-DX 384, and himbacine, showed IC50 values of 24, 
64, and 187 nM, respectively, whereas, for the M3/M1 receptor-preferring 
antagonists, 4-DAMP and p-FHHSiD, IC50 values of 127 and 452 nM were 
determined. Pirenzepine a M1/M4 receptor-preferring antagonist was found to 
have an IC50 value of 1.5 µM. None of the antagonists at any of the 
concentrations studied significantly affected (3H)-thymidine incorporation on its 
own. When the potencies of these antagonists as determined here were 
correlated to their reported affinity constants to cloned human muscarinic 
receptors, the best and highly significant correlation was obtained for the M2 
receptor. Figures 5B-5D present only the correlations for M1, M2, and M3 
receptors, as affinity data of tiotropium for cloned M4 and M5 receptors have not 
yet been published. For these two receptors, the respective correlations 
calculated on the basis of the remaining six antagonist failed to be statistically 
significant, with r = 0.60 and 0.27 for M4 and M5 receptors, respectively. 
Furthermore when correlation significance was calculated as described 
previously for the various muscarinic receptors in the absence of tiotropium, M2 
muscarinic receptor showed the best and highly significant correlation with r = 
0.89 as compared to M3 (r = 0.10), M1 (r = 0.17), M4 (r = 0.60) and M5 (r = 0.27).  
 
 
Figure  5. A. Inhibitory effects of different muscarnic receptor antagonists on carbachol-induced 
stimulation of (3H)-thymidine incorporation in MRC-5 human lung fibroblasts. A total of 7.5 x 104 
cells were seeded in 12-well dishes under FCS-free conditions. Carbachol (10 µM) was added 
from the onset of incubation for a total of 30 h, of which (3H)-thymidine (37 kBq) was present for 
the last 24 h. In the absence of antagonists, carbachol enhanced (3H)-thymidine incorporation by 
98 ± 10% (n = 53). Antagonists were applied immediately before addition of carbachol at the 
concentrations given by the abscissa. Ordinate: stimulatory effect of carbachol in the presence of 
antagonist, expressed as percent of mean stimulatory effect of carbachol in the absence of 
antagonists, as observed in the respective series of experiment. Data are means of n = 3-12 
(mostly n ≥ 6); SEM, 6-12%. 
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Figure 5. B-D. Correlation between the potencies of the antagonists, as determined in the 
present experiments (ordinate), and the reported affinity constants, as determined on cloned 
human muscarnic receptors (abscissa). Open squares, 4-DAMP; closed triangles, AQ-RA741; 
open diamonds, AF-DX384; closed diamonds, p-FHHSiD; closed circles, tiotropium; open circles, 
himbacine; open inverted triangles, pirenzepine. 
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3.3.1.2 Effect of Pertussis Toxin on Muscarinic Stimulation of Proliferation 
of MRC-5 Human Lung Fibroblasts  
Pertussis toxin (PTX) has been widely used as a reagent to characterize the 
involvement of heterotrimeric G-proteins in signalling. This toxin catalyses the 
ADP-ribosylation of specific G-protein subunits of the Gi family, and this 
modification prevents the occurrence of the receptor–G-protein interaction. As 
shown in Figure 6, pretreatment of the fibroblasts with PTX resulted in a slight 
reduction in (3H)-thymidine incorporation, and abolished the stimulatory effect of 
carbachol. In order to test the specificity of PTX, the effects of this toxin were 
also studied on the proliferative effect of PDGF, which is known to act via a 
different class of receptors. Pretreatment of the cells with PTX, as described in 
Figure 6, did not inhibit the PDGF-induced stimulation of (3H)-thymidine 
incorporation (increase by 219 ± 40% [n = 6] and 283 ± 40% [n = 3] in absence 
and presence of PTX, respectively).  
 
Figure 6. Effects of carbachol and/or pertussis toxin (PTX) on (3H)-thymidine 
incorporation in MRC-5 Human Lung Fibroblasts 
(A + B) 7.5 x 104 cells were seeded in 12 well dishes and cultured under FCS-free conditions. 
PTX (0.1 µg/ml) was present from the onset of incubation. Carbachol (Carb., 10 µM), PDGF 100 
ng/ml) were added 3 h after PTX. Finally, (3H)-thymidine (37 kBq) was added 6 h later and 
present for 24 h. Data are means (±SEM) of n=3-12 (mostly n≥6). * P< 0.01 and ** P< 0.001 vs. 
controls (Ctr); *, + P< 0.01 vs. Ctr, and **P< 0.001 vs. Carb, alone. 
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3.3.1.3 Muscarinic Stimulation and Effect of Pertussis Toxin on 
Proliferation in Primary Human Lung Fibroblasts (pHLFb) 
(3H)-thymidine incorporation experiments were performed with primary human 
lung fibroblasts to confirm the muscarinic stimulation mediated proliferation using 
10 µM carbachol or oxotremorine, in the presence of tiotropium or atropine, as 
well as pretreatment with PTX. It was observed that the stimulatory effect in the 
presence of the muscarinic agonists carbachol and oxotremorine were abolished 
in the presence of tiotropium or atropine and PTX. These results were in line with 
those seen for the MRC-5 cell line. Also, in the primary human lung fibroblasts, 
PTX pretreatment failed to inhibit the proliferative effect of 100 ng/ml PDGF 
(increased by 403 ± 49% [n = 12] and 487 ± 80% [n = 3] in the absence and 
presence of PTX, respectively).   
 
Figure 7. Effects of carbachol and/or pertussis toxin (PTX), tiotropium or atropine on (3H)-
thymidine incorporation in Primary Human Lung Fibroblasts.  
7.5 x 104 cells were seeded in 12 well dishes and cultured under FCS-free conditions. Cells were 
incubated for 30 h with carbachol (Carb, 10 µM) and/or tiotropium (T, 0.1 µM), atropine (A, 1 µM) 
or oxotremorine (Oxo, 10 µM) as indicated. (3H)-thymidine (37 kBq) was added 6 h after onset of 
exposure to these drugs. In the respective experiments PTX (0.1 µg/ml) was already present 3 h 
before carbachol. Data are means (±SEM) of n=3-12. ** P < 0.001 vs. controls; + P < 0.01 vs. 
carbachol alone.  
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3.4 Muscarinic Stimulation Mediated Activation of MAPK Pathway in Human 
Lung Fibroblasts 
3.4.1 Muscarinic Receptor Stimulation and Activation of p-42/44 MAPK 
Pathway in Proliferation of Human Lung Fibroblast 
The preceding results confirm the presence of muscarinic receptors and its 
involvement in mediating proliferative effects in both the MRC-5 and the primary 
human lung fibroblasts. The next aspect to look into was to study the cellular 
transduction mechanism involved in the muscarinic stimulation of lung fibroblast 
proliferation. Since activation of MAPK cascade has been shown to be an 
essential transduction mechanism of many mitogens and growth factors, (3H)-
thymidine incorporation assay was performed. Early passage MRC-5 cells were 
used for this purpose and for all experiments; primary cells were used before 
their 7th passage. Cells were disseminated in a 12-well dish at a density of 7.5 x 
104 per well and cultivated in the absence of FCS for 30 hours in combination 
with the test drugs. (3H)-thymidine (37kBq) was applied for the last 24 hours. As 
shown in Figure 8, muscarinic receptor agonist carbachol (10 µM) exerted a 
marked proliferative effect in both, MRC-5 cells and primary human lung 
fibroblasts as indicated by about 2-fold increase in (3H)-thymidine incorporation. 
Preceding results show this effect was inhibited by different muscarinic receptor 
antagonist like atropine and tiotropium proving that proliferation is mediated via 
specific muscarinic receptors. Figure 8, further shows that in both MRC-5 
fibroblasts as well as in primary human lung fibroblasts the stimulatory effect of 
carbachol could be blocked by PD98059, a specific inhibitor of MAPK-activating 
enzyme (MEK), implicating that MAPK cascade is crucially involved in the 
proliferative response of human lung fibroblasts to cholinergic stimulation. 
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Figure 8. Effects of carbachol in absence and presence of PD 98059 on the (3H)-
thymidine incorporation in Primary Human Lung Fibroblast (hLFb) and the Human Lung 
Fibroblast cell line MRC-5. 7.5 x 104 cells were disseminated in 12-well dishes in the absence of 
FCS and cultured for 30 h in the absence and presence of test drug as indicated. The cells were 
pretreated with the PD 98059 drug for 30 min before the addition of the carbachol. (3H)-thymidine 
was applied for the last 24 h. Given are means ± SEM of n = 3-12 (mostly ≥ 6). Significance of 
differences; from controls, *P < 0.05; **P < 0.01; from carbachol, +P < 0.05.   
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3.4.1.2 Western Blot Analysis of p42/44 MAPK (ERK1, ERK2) Activation in 
MRC-5 Human Lung Fibroblast 
Western blot analysis was performed to confirm the activation of the MAPK 
cascade in response to the muscarinic stimulation induced proliferationin the 
MRC-5 fibroblasts at the protein levels. Western blot analysis conducted after a 
two to 120 minute stimulation of serum-starved MRC-5 fibroblasts with carbachol 
or oxotremorine (Figure 9) demonstrated activation of p42/44 MAPK (ERK1, 
ERK2). The effects of both oxotremorine and carbachol revealed to be 
counteractable by the muscarinic receptor antagonists atropine (1 µM, data not 
shown) and tiotropium (0.1 µM, exemplary shown for stimulation by carbachol in 
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Figure 9). Finally, similar activation patterns were observed in primary human 
lung fibroblasts (10 µM carbachol enhanced p42/44 MAPK to 189 ± 12% of 
controls after 10 minutes (n = 6), data not shown).   
 
Figure 9. Western blot analysis of p42/44 MAPK (ERK1, ERK2) activation in MRC-5 
Human Lung Fibroblasts. Cells were cultured in a 55 mm2 dishes to nearly confluence, serum-
starved for 24 h and exposed to 10 µM oxotremorine (Oxo), carbachol (C) in absence or 
presence of 0.1 µM tiotropium or vehicle (Ctr) for 2-120 min as indicated. Cell lysates were 
prepared and 20-50  
µg were separated in 10-20% acrylamide Tris-glycine gels, immobilised to PVDF membranes and 
detected by antibodies specific for phosphorylated MAPK (P-44/42) and unphosphorylated MAPK 
(ERK1/2). Densitometrical quantification of the p-44/42 bands was performed and values 
(arbitrary units) in presence of agonists expressed as % of the the respective control. Given are 
means ± SEM of n = 3-6 independent Western blots. 
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3.5 Effect of Kinase Inhibitors on Muscarinic Stimulation of MRC-5 Human 
Lung Fibroblast Proliferation 
3.5.1 Effects of the Rho-kinase Inhibitor Y27632 on Muscarinic Stimulation 
of MRC-5 Human Lung Fibroblast Proliferation 
The results previously indicated the muscarinic stimulation of proliferation in 
human lung fibroblast is mediated via the classical MEK-ERK MAPK cascade 
pathway. To elucidate the detailed transduction of how muscarinic receptor 
stimulation results in MAPK activation (3H)-thymidine incorporation proliferation 
assays were performed with various antagonists specific to signalling molecules, 
most likely to be involved in this G protein receptor coupled activation of MAPK 
pathway. 
Rho a member of the family of small G-proteins has been shown to mediate cell 
cycle progression and proliferation via the activation of the MAPK cascade. To 
test if Rho was indeed involved in the muscarinic stimulation of proliferation of 
MRC-5 human lung fibroblast (3H)-thymidine incorporation assay was performed. 
Cells were seeded (1.5 x 105 cells/well) in a 12 well dish in the presence or 
absence of FCS and cultured for 30 hours with or without the test drugs. 
Passage numbers 1-10 were chosen for these experiments. The Rho-kinase 
inhibitor Y27632 (10 µM) was added 30 minutes prior to addition of carbachol (10 
µM). As shown in Figure 10 (A + B) using the 30 hours FCS-free or the 6 hours 
10% FCS followed by the FCS-free period protocols prior to addition of the drugs, 
carbachol enhanced the (3H)-thymidine incorporation to 141 ± 4% and 155 ± 10% 
while the Rho-kinase inhibitor Y27632 reduced the (3H)-thymidine incorporation 
to 79 ± 2% and 50 ± 4% with respect to the control. However the Y27632 Rho-
kinase inhibitor did not inhibit the carbachol induced stimulation of (3H)-thymidine 
incorporation (increase to 136 ± 7% and 160 ± 9% respectively in the presence 
of Y27632).  
 
 
 
76 
Figure 10 A + B. Effects of the Rho-kinase inhibitor Y27632 on muscarinic stimulation of 
MRC-5 human lung fibroblast proliferation. MRC-5 cells (1.5 x 105 per well) were disseminated 
in 12 well dishes in the absence or presence of FCS and cultured for 30 h with or without test 
drugs as indicated. The cells were pre-treated with the Rho-kinase inhibitor Y27632 for 30 min 
before the addition of carbachol. (3H)-thymidine was applied for the last 24 h. Given are means ± 
SEM of n=9-18. Significance of differences: from respective controls, *P<0.01. 
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3.5.1.2 Effects of the Phospholipase C Inhibitor U73122 on Muscarinic 
Stimulation of MRC-5 Human Lung Fibroblast Proliferation  
Previous studies have demonstrated the muscarinic stimulation induced 
activation of the MAPK pathway mediated via the Phospholipase C (PLC) in 
pertussis toxin sensitive G-proteins. In order to elucidate the involvement of PLC 
on the muscarinic stimulation of MRC-5 human lung fibroblast proliferation (3H)-
thymidine incorporation assays were performed. Cells in early passages were 
used in these experiments. Cells were disseminated (1.5 x 105 cells per well) in 
12 well dishes in the absence of FCS and cultured for 30 hours with or without 
the test drugs. The PLC-inhibitor U73122 was added 30 minutes prior to the 
addition of carbachol (10 µM) in concentrations of 0.1, 0.3 and 1 µM. As shown in 
Figure 11 (A + B), carbachol caused an increase in the (3H)-thymidine 
incorporation by 193 ± 6% whereas the Phospholipase C inhibitor U73122 
reduced the (3H)-thymidine incorporation significantly to 80 ± 5% and 84 ± 7% at 
0.3 and 1 µM concentrations relative to the control.  However the PLC inhibitor 
U73122 did not inhibit the carbachol induced stimulation of (3H)-thymidine 
incorporation (increase to 224 ± 18% [n = 9] and 183 ± 9% [n = 9] respectively in 
the presence of U73122 at 0.3 and 1 µM).  
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Figure 11 A + B. Effects of the Phospholipase C inhibitor U73122 on muscarinic 
stimulation of MRC-5 human lung fibroblast proliferation. Cells (1.5 x 105 cell/well) were 
disseminated in 12 well dishes in the absence of FCS and cultured for 30 h with or without test 
drugs as indicated. The cells were pre-treated with the phospholipase C inhibitor U73122 for 30 
min before the addition of carbachol. (3H)-thymidine was applied for the last 24 h. Given are 
means ± SEM of n=9-18. Significance of differences: from their respective controls, *P<0.05; 
**P<0.01; ***P<0.01.  
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3.5.1.3 Effects of the PI3-kinase Inhibitor Wortmannin on Muscarinic 
Stimulation of MRC-5 Human Lung Fibroblast Proliferation  
Phosphoinositide 3-kinases (PI3-kinases or PI3Ks) are a family of related 
enzymes that are capable of phosphorylating the 3 position hydroxyl group of the 
inostol ring of phosphatidylinositol. Several studies have documented the 
activation of the MAPK via PI-3 kinase. To investigate the role of PI-3 kinase in 
the muscarinic stimulation of proliferation in MRC-5 human lung fibroblasts (3H)-
thymidine incorporation assays were performed using the PI3-kinase inhibitor 
wortmannin.  Cells in early passages were used in these experiments. Cells were 
disseminated (1.5 x 105 cells per well) in 12 well dishes in the absence of FCS 
and cultured for 30 hours with or without the test drugs. The PI3-kinase inhibitor 
wortmannin was added 30 minutes prior to the addition of carbachol (10 µM) in 
concentrations of 30, 100 and 300 nM. As shown in Figure 12 (A + B) carbachol 
caused an increase in the (3H)-thymidine incorporation by 191 ± 7% whereas the 
PI3-kinase inhibitor wortmannin reduced the (3H)-thymidine incorporation 
significantly to 61 ± 1%,  48 ± 3% and 37 ± 2% at 30, 100 and 300 nM 
concentrations relative to the control. However the PI3-kinase inhibitor 
wortmannin did not inhibit the carbachol induced stimulation of (3H)-thymidine 
incorporation (increase to 189 ± 12%) in the presence of U73122 (100 nM). The 
effect of wortmannin (300 nM) on the carbachol induced proliferation could not be 
considered as a consistent result since the magnitude of the effect showed 
considerable variation and was not significantly different from respective value in 
the absence of wortmannin.   
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Figure 12 A + B. Effects of the PI3-kinase Inhibitor Wortmannin on Muscarinic 
Stimulation of MRC-5 Human Lung Fibroblast Proliferation. Cells (1.5 x 105 cell/well) were 
disseminated in 12 well dishes in the absence of FCS and cultured for 30 h with or without test 
drugs as indicated. The cells were pre-treated with PI3-kinase inhibitor wortmannin for 30 min 
before the addition of carbachol. (3H)-thymidine was applied for the last 24 h. Given are means ± 
SEM of n=9-18. Significance of differences: from controls, *P<0.01; n.s., not significantly different 
from respective value in absence of wortmannin. 
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3.5.1.4 Effects of the Raf-1 Inhibitor GW5074 on Muscarinic Stimulation of 
MRC-5 Human Lung Fibroblast Proliferation  
The RAS/RAF/MEK/ERK signal transduction pathway is a conserved pathway 
that regulates cell growth and signaling. Previous studies have shown the 
involvement of Ras and Raf in the Gi-coupled acetylcholine muscarinic M2 
receptor activation of MAPK, also Ras-independent activation of MAPK mediated 
via the Raf-MEK-MAPK have been reported. To study the role of Raf in the 
muscarinic stimulation of proliferation in MRC-5 human lung fibroblasts (3H)-
thymidine incorporation assay was employed using the Raf-1 inhibitor GW5074. 
Early passages of MRC-5 cell up to passage 10 were used for the purpose of 
these experiments. Cells were disseminated (1.5 x 105 cells per well) in 12 well 
dishes in the absence of FCS and cultured for 30 hours with or without the test 
drugs. The Raf-1 inhibitor GW5074 was added 30 minutes prior to the addition of 
carbachol (10 µM) in concentrations of 0.1, 1 and 3 µM. as indicated in Figure 13 
A +B. carbachol induced a proliferative stimuli, increasing the (3H)-thymidine 
incorporation to 167 ± 6% with respect to the control. The Raf-1 inhibitor 
GW5074 did not affect the basal proliferation rate at 0.1 and 1 µM although at a 3 
µM concentration it inhibited the (3H)-thymidine incorporation to 40 ± 7% relative 
to the control. It was also observed that the carbachol induced muscarinic 
stimulation of proliferation was significantly inhibited by GW5074 at 1 and 3 µM 
as shown by the reduction in the (3H)-thymidine incorporation to 151 ± 6% and 
132 ± 8% in the presence of the drug respectively.   
 
 
 
 
 
 
 
 
82 
Figure 13 A + B.  Effects of the Raf-1 inhibitor GW 5074 on muscarinic stimulation of 
MRC-5 Human Lung Fibroblast proliferation. Cells (1.5 x 105 cell/well) were disseminated in 
12 well dishes in the absence of FCS and cultured for 30 h with or without test drugs as indicated. 
The cells were pre-treated with Raf-1 inhibitor GW5074 for 30 min before the addition of 
carbachol. (3H)-thymidine was applied for the last 24 h. Given are means ± SEM of n=9-27. 
Significance of differences: from controls, *P<0.01; from the respective value in absence of 
GW5074, +P<0.05; ++P<0.01. 
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3.5.1.5 Effects of the Raf-1 Inhibitor GW5074 (GW) on Muscarinic 
Stimulation of the ERK-MAP Kinase in MRC-5 Human Lung Fibroblasts  
Western blot analysis was performed to confirm the inhibitory effect of the Raf-1 
inhibitor GW5074 on the activation of the MAPK cascade in response to the 
muscarinic stimulation induced proliferation in the MRC-5 fibroblasts at the 
protein levels. Western blot analysis conducted after a two minute stimulation of 
serum-starved MRC-5 fibroblasts with carbachol (10 µM) demonstrated activation 
of p42/44 MAPK (ERK1, ERK2). Densitometrical quantification of the p-44/42 
bands was performed and values (arbitrary units) revealed that carbachol (10 
µM) enhanced p-44/42 MAPK to 249 ± 61% (n =3) while GW5074 by itself did 
not appear to affect the MAPK activation with respect to the control, the 
carbachol enhaced p-44/42 MAPK was reduced to 186 ± 36% (n = 3) in the 
presence of the Raf-1 inhibitor.    
 
Figure 14. Effects of the Raf-1 inhibitor GW5074 (GW) on muscarinic stimulation of the 
ERK-MAP kinase in MRC-5 Human Lung Fibroblasts.  Cells were cultured in a 55 mm2 dishes 
to nearly confluence, serum-starved for 24 h and exposed to 10 µM carbachol (C) in absence or 
presence of 3 µM GW5074 or vehicle (Ctr) for 2 minutes. Cell lysates were prepared and 20-50  
µg were separated in 10-20% acrylamide Tris-glycine gels, immobilised to PVDF membranes and 
detected by antibodies specific for phosphorylated MAPK (P-44/42) and unphosphorylated MAPK 
(ERK1/2).  
                                                              ---- GW ---- 
 P 42/44                    
   ERK-1/2           
                   -      c           -        c 
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3.5.1.6 Effects of the Tyrosine-Kinase Inhibitor Tyrphostin AG1295 on 
Muscarinic Stimulation of MRC-5 Human Lung Fibroblasts 
Protein tyrosine kinases (PTKs) play a key role in normal cell and tissue 
development. Enhanced PTK activity is intimately correlated with cell 
proliferation. Numerous studies have shown that GPCRs may utilize receptor 
tyrosine kinases (RTKs) such as platelet derived growth factor receptor (PDGF) 
or epidermal dervived growth factor receptor (EGFRs) as intermediate signaling 
proteins thereby mimicking the signaling pathways downstream leading to 
activation of MAPK cascade. To investigate whether muscarinic stimulation of 
MRC-5 human lung fibroblast lead to the transactivation of PDGF receptor, (3H)-
thymidine incorporation assays were performed in the presence or absence of 
tyrphostin AG1295 a specific tyrosine kinase inhibitor for PDGF receptors. As 
shown in Figure 15 A + B. carbachol (10 µM) caused an increase in the (3H)-
thymidine incorporation to 175 ± 5% while tyrphostin AG1295 (5 µM) inhibited 
(3H)-thymidine incorporation to 29 ± 4% with respect to the control.  However the 
tyrphostin AG1295 the tyrosine kinase inhibitor did not inhibit the carbachol 
induced stimulation of (3H)-thymidine incorporation (increase to 175 ± 9%) in the 
presence of tyrphostin AG1295 (5 µM). In a further set of control experiments 
(data not shown [n = 3]) it was observed that the PDGF (10 ng/ml) induced 
increase in (3H)-thymidine incorporation in MRC-5 human lung fibroblast was 
unimpeded in the presence of tiotropium (1 µM), confirming its selectivity in 
inhibition of carbachol induced muscarinic proliferation of MRC-5 human lung 
fibroblast.  
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Figure 15 A + B Effect of tyrosine-kinase inhibitor tyrphostin AG1295 on muscarinic 
stimulation of MRC-5 human lung fibroblast. Cells (1.5 x 105 cell/well) were disseminated in 
12 well dishes in the absence of FCS and cultured for 30 h with or without test drugs as indicated. 
The cells were pre-treated with tyrosine kinase inhibitor AG1295 for 30 min before the addition of 
carbachol. (3H)-thymidine was applied for the last 24 h. Given are means ± SEM of n=9-18. 
Significance of differences: from controls, **P<0.01  
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3.6 Muscarinic Stimulation of proliferation of MRC-5 Human Lung 
Fibroblast and Anti-apoptotic effects 
Apoptosis represents a multi-step process for elimination and subsequent 
removal of cells in response to environment insults or as part of organismal 
development. The caspases are a family of proteins that are one of the main 
executors of the apoptotic process. They belong to a group of enzymes known as 
cysteine proteases which can be activated following the occupation of certain cell 
surface ‘death’ receptors (e.g. tumor necrosis factor) or by agents that induce 
stress or DNA damage (e.g. actinomycin D, cycloheximide). A member of this 
family, caspase-3 has been identified as being a key mediator of apoptosis of 
mammalian cells. The previous experiments that were performed clearly 
indicated the functional role of the muscarinic receptors in the carbachol induced 
proliferation of the MRC-5 human lung fibroblasts cells. Various studies 
performed in the past have confirmed the anti-apoptotic effects of the G-protein 
coupled muscarinic receptor activation 
 The next aspect that was explored was whether the proliferative stimuli 
mediated via the muscarinic receptors in the MRC-5 fibroblasts were augmented 
by an anti-apoptotic effect concomitantly. For this purpose caspase-3 fluorimetric 
assays were performed using a combination of apoptosis inducers like TNFα, 
actinomycin D and cycloheximide in the presence or absence of the muscarinic 
agonist carbachol. MRC-5 cells (4 x 104 cells/well) were disseminated in 24-well 
dishes in the presence of 10% FCS, upon confluence the medium was aspirated 
out cells were treated with apoptosis inducers in the presence or absence of 
carbachol (10 µM) as indicated in Figure 16, and incubated further for 4 hours 
under serum-free conditions followed by lysis and treatment with the substrate. 
Two wells for substrate blank, two for caspase positive control and two for 
caspase positive in combination with the caspase inhibitor were also prepared for 
every experiment. As shown in Figure 16, actinomycin D in presence of TNFα 
and cycloheximide in combination with TNFα enhanced  capase-3 activity to 119 
± 2%, 176 ± 40% respectively relative to the control. The positive control showed 
an increased caspase- 3 activity to 203 ± 11% which was reduced to 127 ± 10% 
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with respect to the control in the presence of the caspase inhibitor. Nonetheless it 
was observed that carbachol (10 µM) did not significantly affect the level of 
caspase-3 activity in the presence of the either of the two combinations of the 
apoptosis inducers. Although these results seem to suggest that the carbachol 
induced muscarinic proliferation of MRC-5 human lung fibroblasts is unaided by 
anti-apoptotic mechanisms the magnitude of the effect showed considerable 
variations hence could not be considered conclusive.  
 
Figure 16.  Effects of various apoptosis inducers on muscarinic stimulation of MRC-5 
Human Lung Fibroblast using caspase-3 fluorimetric assay. 
 Cells (4 x 104 cell/well, passages 14, 15 and 16)) were disseminated in 24 well dishes in the 
presence of 10% FCS upon confluence the medium was changed to serum free with the addition 
of TNFα (TNFalphaH) 10 ng/ml, Actnomycin D 200 ng/ml, Cycloheximide 10 µg/ml, Carbachol 10 
µM, Caspase positive 0.05 µg/ml and Caspase inhibitor 2 µM as indicated and incubated for 4 h 
followed by lysis and substrate addition. Given are means ± SEM of n = 6 for 3 sets of 
experiments. Significance of differences: from controls, *P<0.05, **P<0.01 (paired t-test). 
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3.7 Nicotinic Receptor Expression and Function in MRC-5 Human Lung 
Fibroblasts  
Semi-quantitative RT-PCR’s were performed to determine the expression pattern 
of the mRNA encoding for the different nicotinic receptors subunit subtypes in 
MRC-5 fibroblast cell line. Total RNA was isolated as described previously and 
first-strand cDNA was synthesized using Omniscript reverse transcriptase. Then 
the PCR amplification was carried out using specific oligonucleotide primers for 
human nicotinic receptors (α1-α7, α9, α10 and ß1-ß4) or ß-actin in a programmable 
thermal cycler set to 23 cycles for ß-actin and 35 cycles for nicotinic receptors.   
Positive controls were performed for every PCR using genomic DNA (gDNA) 
isolated for MRC-5 cells and one PCR lacking template DNA was regularly 
performed as a negative control. Table B, shows the PCR product size and the 
specific annealing temperature for the primers pairs employed. 
As shown in Figure 17 A + B, MRC-5 fibroblasts express mRNA encoding 
different nicotinic receptor subunit subtypes. The most prominent expression was 
found for mRNA encoding α1 subunit, followed by α7, α5 subunit transcripts 
respectively. Slightly lower expression of mRNA encoding for α3 and ß1 subunit 
was also observed. The expression pattern for the mRNA encoding the nicotinic 
receptors subunit subtypes was found to be consistent under the culture 
conditions, as a similar pattern was found in different passages (passages 5-7). 
Studies conducted previously have implicated α7 nicotinic receptors subunits 
increased expression associated with lung fibroblast proliferation. To explore the 
possibility of a cross talk between the muscarinic and nicotinic receptors 
expressed in the MRC-5 fibroblast cells (3H)-thymidine incorporation assays were 
performed using nicotinic agonist and antagonist in the presence or absence of 
carbachol. Nicotine did not appear to either affect proliferation by itself nor in the 
presence of carbachol (data not shown) although there was some indication that 
the muscarinic agonist carbachol induced increase in (3H)-thymidine 
incorporation was supplemented in the presence of hexamethonium a nicotinic 
antagonist, but the extent of the effect showed considerable variation over a 
range of experiments making it impossible to be considered as a true effect. 
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 Table B 
Receptor Primer pair Product size (bp) Annealing 
temperature oC 
hα1 α1-hnACHR-s 
α1-hnACHR-as 
233 55 
hα3 α3-hnACHR-s 
α3-hnACHR-as 
419 52 
hα5 α5-hnACHR-s 
α5-hnACHR-as 
324 64 
hα7 α7-hnACHR-s 
α7-hnACHR-as 
308 55 
hß1 ß1-hnACHR-s 
ß1-hnACHR-as 
455 51.9 
 
Figure 17. Expression of human nicotinic receptors in MRC-5 Human Lung Fibroblasts. 
A. Samples of RT-PCRs of human nicotinic receptors on RNA isolated from MRC-5 human lung 
fibroblasts. Cells were grown in 55-mm culture dishes to confluence, total RNA was isolated, 
treated with DNase, and used for RT-PCR with primers specific for the human nicotinic receptors 
or ß-actin. To control effectiveness of primer pairs, PCRs were also performed on genomic DNA 
(gDNA) isolated from MRC-5 cells. One PCR lacking template DNA was regularly performed to 
account for any contamination (negative control, -Ctr.). PCR products were separated on a 1.2% 
agarose gel. 
B. Densitometric evaluation of a series of experiments. Given are mean values (+SEM) of three 
experiments performed with cells of passages 5-7. Values were normalized for ß-actin to correct 
for quality of cDNA preparation  
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4. Discussion 
4.1 Muscarinic Receptor Expression in Human Lung Fibroblasts 
Almost every cell type in the lung and airways expresses cholinoceptors, but 
expression of muscarinic receptors in lung fibroblasts has not been characterized 
yet. For this purpose semi-quantitative RT-PCR’s were performed using both the 
MRC-5 as well as the primary human lung fibroblasts. Our results demonstrated 
that muscarinic receptors were expressed in both MRC-5 and primary human 
lung fibroblasts. In both, the cell line and primary cells the strongest mRNA 
expression was observed for M2 receptor, whereas some gradual differences 
were found with regard to the other muscarinic receptors. In MRC-5 cells the 
levels of mRNA encoding M3 receptor appeared to be higher than in the primary 
cells, which on the other hand seem to express a clear message for M1 receptor. 
As mentioned before the genes of muscarinic receptors are intronless. Therefore, 
the RNA preparations were treated with DNase prior to the RT reaction to 
exclude any contamination with genomic DNA. The differential expression 
pattern observed in the present study, in particular the lack of PCR products 
accounting for M1 and M5 receptors in MRC-5 and primary lung fibroblasts, 
respectively, argues against an artefact. Moreover, in MRC-5 cells the 
expression of M2 and M3 receptors could be confirmed at the protein level by 
Western blot analysis. Finally to confirm the regional expression pattern of mRNA 
encoding for muscarinic receptors M2 and M3 semi-quantitative RT-PCRs were 
performed using primary fibroblast cultures obtained from peripheral and distal 
region of the human lung and our results showed that again in this case mRNA 
encoding M2 receptor subtype was dominantly expressed followed by a slightly 
lower expression of mRNA encoding for M3 receptor subtype. 
  
4.2 Muscarinic Stimulation of Proliferation of Human Lung Fibroblasts 
Subsequent to our findings that human lung fibroblasts expressed muscarinic 
receptors we investigated further to see if these receptors did play a part in 
mediating proliferative response. For this purpose proliferation studies were 
performed using a range of protocols to determine the optimal parameters which 
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then could be set as a standard for the remaining proliferation studies that would 
ensue. The proliferation of lung fibroblasts in vitro largely depends on the 
presence of FCS which obviously contains a cocktail of diverse factors promoting 
fibroblast growth. Consequently, the effects of muscarinic agonists were first 
tested in FCS-deprived conditions, i.e. in absence of other mitogenic stimuli. 
Under these conditions carbachol and oxotremorine caused an increase in (3H)-
thymidine incorporation in MRC-5 cells and primary human lung fibroblasts. In 
both cell types, the proliferative effects of carbachol or oxotremorine were 
blocked by the muscarinic antagonist atropine and the long acting muscarinic 
antagonist tiotropium at concentrations at least 10- and 100-fold lower than those 
of the agonists, proving the involvement of specific muscarinic receptors. The 
antagonists had no effect on their own, which excludes significant effects of non-
neuronal acetylcholine under the present culture conditions.  
In MRC-5 cells the muscarinic stimulation of proliferation was studied in more 
detail. The stimulatory effect of carbachol appeared to be somewhat more 
pronounced when the drug was added after dissemination isochronal to FCS-
deprivation and when it was present already prior to the (3H)-thymidine exposure 
compared to conditions where the agonist was applied at the same time with 
(3H)-thymidine only for the last part of the incubation period. This may suggest 
that the muscarinic mitogenic stimulus is slowly developing, but long lasting. A 
mitogenic effect of muscarinic agonists has also been demonstrated on airway 
smooth muscle (10, 11), but in contrast to the present observations on 
fibroblasts, muscarinic agonists alone showed no proliferative effect in airway 
smooth muscle, but augmented the effect of other mitogenic stimuli such as 
platelet-derived growth factor (PDGF) or epidermal growth factor (EGF). The 
present experiments showing that the proliferative effects of carbachol and 
oxotremorine were basically the same in absence or presence of 1% FCS, 
indicate that in human lung fibroblasts the proliferative effects induced by 
muscarinic receptor activation may be additive to proliferative effects caused by 
other mitogenic stimuli. 
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4.3 Inhibition of Muscarnic Proliferation using Receptor Sub-Type Specific 
Antagonists in MRC-5 Human Lung Fibroblasts and Effect of Pertussis 
Toxin on Muscarinic Stimulation of Proliferation of Human Lung 
Fibroblasts  
Our previous results indicate that human lung fibroblasts do express muscarinic 
receptors and that they mediated proliferative effects. Both, M2 and/or M3 
receptors have been shown to mediate activation of the mitogen-activated 
protein kinase/extracellular signal–regulated kinase 1/2 pathway (188, 190, 191), 
which is known to mediate proliferative responses in various cell types (192, 193, 
194). In order to characterize the muscarinic receptor subtype mediating the 
proliferative effect in MRC-5 fibroblasts the M2/M4 receptor preferring antagonists 
AF-DX 384 , AQ-RA 741 and himbacine, the M3/M1 receptor preferring 
antagonists 4-DAMP and p-FHHSiD and the M1/M4 receptor preferring antagonist 
pirenzepine were tested in addition to tiotropium. It should be emphasized that 
the subtype selectivity of the currently available “selective” muscarinic receptor 
antagonists is rather limited. Usually they show a relatively high potency at least 
for two of the five muscarinic receptors and the potency difference to the other 
muscarinic receptors is only about one order of magnitude. Nonetheless, 
comparing the potency of a series of subtype preferring antagonists is an 
approach to deal with this problem (195). When the antagonist potencies as 
observed in the present experiments were correlated to their reported affinity 
constants on cloned human muscarinic receptors (71, 196), by far the best 
correlation was obtained for the M2 receptor, supporting the assumption that this 
muscarinic receptor subtype may be essential in mediating the proliferative 
effects. This correlates well with the observation that at the mRNA level M2 
receptors represented the major muscarinic receptor subtype in these cells. In 
line with this conclusion is also the observation, that pertussis toxin abolished the 
effect of carbachol, since pertussis toxin is known to inhibit Gi/o, G proteins to 
which only M2 and M4 receptors couple (196). An unspecific antiproliferative 
action of the PTX may be excluded, as PTX did not inhibit the proliferative effect 
of PDGF, which is known to exert its effects via activation of a tyrosine kinase 
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receptor, a class of receptors different from G-protein-coupled receptors. 
Therefore, the PTX-induced reduction of baseline proliferation may reflect a 
background activation of Gi-mediated effects, possibly caused by paracrine 
mediators (as, for example, chemokines) released by the fibroblasts themselves. 
The long-acting muscarinic antagonist tiotropium was by far the most potent 
antagonist. The affinity constants of tiotropium are similar for M1, M2 and M3 
receptors, but the dissociation of the respective receptor complexes shows 
different kinetics, with the longest half-life for the M3 receptor (196). This kinetic 
subtype selectivity of tiotropium may not be of significance in the present 
experiments, because they were performed under equilibrium conditions. 
Whether the kinetical subtype selectivity of tiotropium is of clinical importance is 
still debatable (197). Because the half-life of the tiotropium-M2 receptor complex, 
although shorter than that of the M3 receptor complex, is still 3.6 hours (196), it 
may be expected that tiotropium causes a significant blockade of M2 receptors in 
the lung under clinical conditions. 
Although detailed pharmacological experiments have only been performed on 
MRC-5 cells, the observations that pertussis toxin abolished the proliferative 
effect of carbachol also in primary human lung fibroblasts and that the M2 
receptor mRNA represented the predominant muscarinic receptor mRNA in 
these cells as well suggest that also in primary human lung fibroblasts M2 
receptors might mediate the proliferative stimulus. 
 
4.4 Muscarinic Receptor Stimulation and Activation of p-42/44 MAPK 
Pathway in Proliferation of Human Lung Fibroblast 
Our findings from the present study indicate that human lung fibroblasts do 
indeed express muscarinic receptors and that they mediate proliferation in 
pertussis toxin-sensitive manner. Mitogen-activated protein kinase (MAP kinase) 
/ extracellular signal–regulated kinase 1/2 (ERK-1/2) is one of the classical 
pathways mediating proliferative responses induced by various stimuli including 
activation of G-protein coupled receptor (192, 193, 194, 198), and also 
muscarinic receptors (both, M2 and M3) have been shown to be able to activate 
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this pathway (188, 190, 191). Therefore to probe if muscarinic receptor 
stimulation in human lung fibroblasts leads to the activation of MAPK pathway 
functional studies were performed using PD98059 a specific inhibitor for MAPK-
activating enzyme (MEK). Our results demonstrated that the carbachol induced 
muscarinic proliferation in human lung fibroblasts was completely inhibited by 
PD98059, moreover in Western blot analysis carried out with MRC-5 human lung 
fibroblasts it was observed that the carbachol and oxotremorine induced 
activation of p-42/44 MAPK was blocked by muscarinic receptor antagonists 
tiotropium and atropine. These observations strongly support the conclusion that 
muscarinic stimulation of proliferation in human lung fibroblasts is mediated via 
the classical MEK-ERK MAPK cascade. 
 
4.5 Intracellular Signaling Mechanism Involved in Muscarinic Stimulation 
Mediated Activation of MAPK Cascade in MRC-5 Human Lung Fibroblast 
Proliferation 
4.5.1 Effects of the Rho-kinase Inhibitor Y27632 on Muscarinic Stimulation 
of MRC-5 Human Lung Fibroblast Proliferation 
Our previous results demonstrated that the muscarinic stimulation of proliferation 
in human lung fibroblasts is mediated via the classical MEK-ERK MAPK cascade 
in a pertussis toxin sensitive manner. Rho a member of the family of small G-
proteins has been shown to mediate cell cycle progression and proliferation via 
the activation of the MAPK cascade. Rho kinase, a key Rho effector has been 
implicated in the activation of MAPK pathway. In a previous study it was shown 
that inhibition of Rho kinase blocked the Ras transformation in NIH3T3 cells 
(144). Furthermore serotonin stimulation of bovine pulmonary artery VSMC lead 
to the translocation of ERK to the nucleus, and this response was inhibited by 
treatment with either dominant negative RhoA or the Rho kinase inhibitor Y27632 
(149). Therefore to investigate the role of Rho in muscarinic stimulation mediated 
proliferation in MRC-5 human lung fibroblasts we performed (3H)-thymidine 
proliferation assay using the selective Rho kinase inhibitor Y27632. In both the 
protocols that were tested be it the 6 hours 10% FCS period prior to addition of 
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drugs or the one with the FCS free conditions for the duration of the assay it was 
observed that carbachol induced more than 2-fold increase in (3H)-thymidine 
incorporation and the Rho kinase inhibitor Y27632 by itself inhibited the basal 
proliferation level but failed to inhibit the carbachol induced (3H)-thymidine 
incorporation. These results indicate that although Rho does mediate proliferative 
signals in these cells, it is not involved in the muscarinic stimulation mediated 
activation of MAPK in MRC-5 human lung fibroblast cells. 
 
4.5.1.2 Effects of the Phospholipase C Inhibitor U73122 on Muscarinic 
Stimulation of MRC-5 Human Lung Fibroblast Proliferation 
The receptor mediated activation of PLC leads to the generation of two second 
messengers, inositol1,4,5-triphosphate (IP3) and diacylglycerol (DAG). It has 
been well established that IP3 can cause an increase in the concentration of 
intracellular calcium as a result of intracellular storage mobilization and DAG can 
activate the protein kinase C (PKC). The activation of the ERK1/2 pathway 
involving PKC activation following the activation of PLC pathway with production 
of DAG has been previously reported. Therefore we speculated a role for PLC 
and its generated second messengers in linking the activation of muscarinic 
acetylcholine receptors to downstream activation of MAPK in MRC-5 human lung 
fibroblast cells. To investigate the role of PLC, in the present study we performed 
(3H)-thymidine incorporation assays using U73122 a selective PLC inhibitor. Our 
results demonstrate that although the PLC inhibitor U73122 inhibited the basal 
level of (3H)-thymidine incorporation it failed to inhibit the carbachol induced 
increase in the (3H)-thymidine incorporation. Various studies have reported that 
PLC is the principal effector of Gq-mediated signaling. Activation of ERK1/2 by 
the odd numbered muscarinic receptors has been shown to typically involve PKC 
activation following Gq/11 activation of PLC pathway with production of DAG. On 
the other hand M2 and M4 muscarinic receptors have been shown to produce 
only weak activation of PLC pathway (40, 41, 42, 199). Our previous results have 
indicated that the muscarinic stimulation mediated activation of MAPK in human 
lung fibroblasts follows a pertussis toxin sensitive mechanism via the Gi/o protein 
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which correlates well with our finding that PLC inhibition did not inhibit the 
carbachol induced (3H)-thyimidine incorporation in MRC-5 human lung fibroblast 
cells. The decrease in the basal level of (3H)-thymidine incorporation in the 
presence of the PLC inhibitor U73122 could be explained possibly by the fact 
that U73122 could act on other sites in addition to PLC inhibition. Such 
mechanisms include the inhibition of both the intracellular calcium channels, 
which are activated by formation of IP3 by PLC, and plasma membrane bound 
calcium channels (200). In the absence of carbachol stimulation, muscarinic 
receptor coupled PLC is inactive and thus intracellular calcium channels 
activated by IP3 are closed. On the other hand plasma membrane bound calcium 
channels are independent of PLC activation and may play a role in transient 
calcium currents. Therefore, U73122 may antagonise plasma membrane calcium 
channels and as a result decrease the basal levels of (3H)-thymidine 
incorporation.  
 
4.5.1.3 Effects of the PI3-kinase Inhibitor Wortmannin on Muscarinic 
Stimulation of MRC-5 Human Lung Fibroblast Proliferation  
Phosphoinositide 3-kinases (PI3-kinases or PI3Ks) are a family of related 
enzymes that are capable of phosphorylating the 3 position hydroxyl group of the 
inositol ring of phosphatidylinositol. Previously, Lopez-IIasaca et al. (1998) have 
demonstrated that the p42 MAPK activation by G-protein-coupled receptors can 
be mediated by PI3K through a process that requires G-proteins βγ-subunits. 
The wortmannin-sensitive PI3K isoenzyme, PI3Kγ, can be activated by both the 
α and the βγ subunits of the heterotrimeric G-proteins (150). Several studies 
have reported on the regulation of different phosphatidylinositol kinases and 
phosphoinositide pools by muscarinic acetylcholine receptors. Hence to 
investigate whether the PI-3 kinase was crucially involved in the activation of the 
MAPK pathway, in the muscarinic stimulation of proliferation in MRC-5 human 
lung fibroblasts we performed (3H)-thymidine incorporation assays using the PI3-
kinase inhibitor wortmannin. Our results demonstrate that although PI3K is 
involved in mediating proliferative signals in these cells the carbachol induced 
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(3H)-thymidine incorporation is unaffected by the PI3K inhibitor wortmannin thus 
suggesting that PI3K may not be implicated in the carbachol mediated process. 
 
4.5.1.4 Effects of the Raf-1 Inhibitor GW5074 on Muscarinic Stimulation of 
MRC-5 Human Lung Fibroblast Proliferation  
The RAS/RAF/MEK/ERK signal transduction pathway is a conserved pathway 
that regulates cell growth and signaling. Previous studies have shown the 
involvement of Ras and Raf in the Gi-coupled acetylcholine muscarinic M2 
receptor activation of MAPK, also Ras-independent activation of MAPK mediated 
via the Raf-MEK-MAPK have been reported. Hence to elucidate the role of Raf in 
the muscarinic stimulation of proliferation in MRC-5 human lung fibroblasts we 
performed (3H)-thymidine incorporation using the Raf-1 inhibitor GW5074. Our 
results demonstrated Raf-1 inhibitor GW5074 did not affect the basal proliferation 
rate at 0.1 and 1 µM although at a 3 µM concentration it inhibited the (3H)-
thymidine incorporation to 40 ± 7% relative to the control. It was also observed 
that the carbachol induced muscarinic stimulation of proliferation was significantly 
inhibited by GW5074 at 1 and 3 µM as shown by the reduction in the (3H)-
thymidine incorporation to 151 ± 6% and 132 ± 8% in the presence of the drug 
respectively. Furthermore Western blot analysis carried out to confirm the 
inhibitory effect of the Raf-1 inhibitor on the activation of the MAPK cascade in 
response to the muscarinic stimulation induced proliferation in the MRC-5 
fibroblasts at the protein levels showed that while GW5074 by itself did not 
appear to affect the MAPK activation, the carbachol induced increase in MAPK 
activity was inhibited in the presence of the Raf-1 inhibitor. These findings show 
that Raf-1 is indeed involved in the muscarinic stimulation mediated activation of 
MAPK cascade in MRC-5 human lung fibroblast cells and is a signal upstream of 
the MEK-ERK-MAPK cascade. Raf proteins are the conserved signaling module 
that transducer signals from the cell surface to the receptor wherein the Ras 
family of small G-proteins have been shown to be the upstream regulators in 
several cell types. One of the critical steps in the Ras-Raf-MEK cascade is the 
post translational lipid modification of Ras which aids the Ras protein to attach to 
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the cell membrane; this process involves the enzyme farnesyl transferase. Hence 
we performed (3H)-thymidine incorporation assays using farnesly transferase 
inhibitors, however the inhibitor of Ras farnesyl transferase FTI-277 (up to 3 µM) 
did not affect carbachol-stimulated (3H)-thymidine incorporation, whereas 
manumycin, a chemically different Ras inhibitor, exerted large cytotoxic effects. 
Therefore making it impossible to draw any conclusions about the role of Ras in 
the muscarinic stimulation mediated activation of MAPK in MRC-5 human lung 
fibroblast cells. 
 
4.5.1.5 Effects of the Tyrosine-Kinase Inhibitor Tyrphostin AG1295 on 
Muscarinic Stimulation of MRC-5 Human Lung Fibroblasts 
Receptor transactivation refers to the ability of a primary agonist, via binding to 
its receptor, to activate a receptor for another ligand via signaling events. 
Transactivation of various growth factor receptors, including the epidermal 
growth factor receptor (EGFR), and the platelet derived growth factor (PDGF), by 
G-protein-coupled receptors has been documented in multiple cellular model 
systems (163, 164, 165, 166, 167). Studies have shown that GPCRs may utilize 
receptor tyrosine kinases (RTKs) such as platelet derived growth factor receptor 
(PDGF) or epidermail dervived growth factor receptor (EGFRs) as intermediate 
signaling proteins thereby mimicking the signaling pathways downstream leading 
to activation of MAPK cascade. To explore the possibility of whether muscarinic 
stimulation of MRC-5 human lung fibroblast lead to the transactivation of PDGF 
receptor, (3H)-thymidine incorporation assays were performed using tryphostin 
AG1295 a specific tyrosine kinase inhibitor for the PDGF receptors. Our findings 
show that although tryphostin AG1295 inhibited the basal level of (3H)-thymidine 
incorporation it did not inhibit the carbachol induced (3H)-thymidine incorporation 
excluding transactivation of receptor tyrosine kinase as a signaling pathway 
mediated via the carbachol stimulated G-protein coupled stimulation of MRC-5 
human lung fibroblast cells. Studies performed by other groups in our laboratory 
using human lung fibroblasts showed that PDGF (10 ng/ml) induced almost a 
one fold increase in the (3H)-thymidine incorporation confirming its strong 
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stimulatory effect on proliferation and this effect was potently inhibited by the 
tyrosine kinase inhibitor tyrphostin AG1295 (5 µM). In a further set of control 
experiments it was observed that the PDGF induced increase in (3H)-thymidine 
incorporation in MRC-5 human lung fibroblast was unimpeded in the presence of 
tiotropium confirming its selectivity in inhibition of carbachol induced muscarinic 
proliferation of MRC-5 human lung fibroblast.  
 
4.6 Muscarinic Stimulation of Proliferation of MRC-5 Human Lung 
Fibroblast and Anti-apoptotic Effects 
Apoptosis represents a multi-step process for elimination and subsequent 
removal of cells in response to environment insults or as part of organismal 
development. Pro-apoptitic singaling may be mediated by the specific ligands 
and surface receptors or can also be activated from inside the cell through 
specific cell sensors residing in the cell nucleus and cytoplasm. The caspases 
are a family of proteins that are one of the main executors of the apoptotic 
process. They belong to a group of enzymes known as cysteine proteases which 
can be activated following the occupation of certain cell surface ‘death’ receptors 
(e.g. tumor necrosis factor) or by agents that induce stress or DNA damage (e.g. 
actinomycin D, cycloheximide). A member of this family, caspase-3 has been 
identified as being a key mediator of apoptosis of mammalian cells. The 
repertoire of signaling pathways controlled by GPCRs has recently been 
extended by studies linking GPCRs to the regulation of apoptosis. Depending on 
the receptor subtypes and the cell type in which the receptor is expressed, 
GPCRs can either induce apoptosis or protect cells from apoptotic stimuli. 
Prominent among the GPCRs that protect cells from apoptotic stimuli are the 
subtypes of the muscarinic receptor family (186, 187). Previous studies have also 
shown that muscarinic receptors that couple to the Gq/11 protein (e.g. M1, M3 and 
M5) can protect cells from apoptosis following DNA damage whereas those 
coupled to the Gi-proteins (M2 and M4) have no protective properties (186). The 
previous experiments that were performed clearly indicated the functional role of 
the muscarinic receptors in the carbachol induced proliferation of the MRC-5 
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human lung fibroblasts cells. Hence we explored the possibility whether the 
proliferative stimuli mediated via the muscarinic receptors in the MRC-5 
fibroblasts were augmented by an anti-apoptotic effect concomitantly. Our 
studies performed by means of the caspase-3 activity as a marker for the level of 
apoptotic signaling using a combination of apoptosis inducers in the presence or 
absence of muscarinic stimuli in MRC-5 human lung fibroblasts suggests that the 
muscarinic mediation of proliferation in these cells is unaided by anti-proliferative 
effects mediated via the muscarinic stimulation. These findings appear to 
correlate well with our previous findings that in MRC-5 human lung fibroblasts the 
muscarinic stimulation mediated proliferation is via the M2 muscarinic receptor 
subtype and also literature which has attributed the anti-proliferative effects 
mediated via muscarinic receptors to the odd numbered muscarinic subtypes. 
However because of the considerably large variation in the magnitude of effects 
over a range of experiments it makes it difficult to positively conclude the 
relationship between the muscarinic stimuli mediated proliferation and its anti-
apoptotic effects in MRC-5 human lung fibroblasts. We speculate that a  study 
done on the regulation of pro/anti-apoptotic genes during muscarinc stimulation 
mediated proliferation in MRC-5 human lung fibroblasts might probably helps 
shed more light on this interaction.  
 
4.7 Nicotinic Receptor Expression and Function in MRC-5 Human Lung 
Fibroblasts 
The α-7 nicotinic receptor subunit has been detected in many non-neuronal cells 
such as the bronchial epithelial cells, endothelial airway cells and airway 
fibroblasts (16). In vitro studies carried out on bronchial epithelial cells and 
pulmonary neuroendocrine cells indicated nicotinic receptor mediated activation 
of cell proliferation cascade (31, 32). Furthermore studies carried out on WI38 
cells, a human embryonic pulmonary fibroblast cell line showed an expression of 
α-3 and α-7 nicotinic receptor subunits. Hence we performed semi-quantitative 
RT-PCRs to explore the expression pattern of nicotinic receptor subunits in 
MRC-5 human lung fibroblasts. Our results demonstrated the expression of α1, 
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α3, α5, α7 and β1 nicotinic receptor subunits in MRC-5 human lung fibroblasts with 
the most dominant expression of α1 subunit followed by α7 subunit. Studies 
conducted previously have implicated an increased expression of α7 subunit of 
nicotinic receptors with lung fibroblast proliferation. To explore the possibility of a 
cross talk between the muscarinic and nicotinic receptors expressed in the MRC-
5 fibroblast cells we performed (3H)-thymidine incorporation assays using 
nicotinic agonist and antagonist in the presence or absence of carbachol. Our 
results demonstrated that nicotine did not appear to either affect proliferation by 
itself nor in the presence of carbachol although there was some indication that 
the muscarinic agonist carbachol induced increase in (3H)-thymidine 
incorporation was supplemented in the presence of hexamethonium a nicotinic 
antagonist, but the extent of the effect showed considerable variation over a 
range of experiments making it impossible to be considered as a true effect. 
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5. Conclusion 
Fibrotic alteration and airway remodeling are pathological features associated 
with asthma and COPD and almost every cell type in the airways expresses 
cholinoceptors. However, only fragmentary knowledge exists with regards to the 
expression and function of muscarinic receptors in pulmonary fibroblasts. To 
characterize the expression pattern of muscarinic receptors we performed semi-
quantitative RT-PCR studies which showed that human lung fibroblasts indeed 
expressed muscarinic receptors with the most dominantly expressed subtype 
being the M2 followed by the M3 muscarinic receptor. Since confirming the 
expression of muscarinic receptors in human lung fibroblasts we explored its 
functional role in mediating proliferation using muscarinic agonists such as 
carbachol and oxotremorine and it was observed that the muscarinic stimulation 
indeed mediated proliferation in human lung fibroblast cells which was 
completely blocked in the presence muscarinic antagonist such as atropine or 
tiotropium. To further explore the muscarinic receptor subtype involved in 
mediating this proliferative response, receptor subtype characterization studies 
were performed using various muscarinic receptor subtype preferring 
antagonists. The pharmacological profile obtained by comparing the potency of 
several subtype preferring antagonists to inhibit the proliferative effect of 
carbachol with reported affinity constants of these antagonists at cloned 
muscarinic receptors indicated that muscarinic stimulation of proliferation of 
human lung fibroblasts was mediated via M2 receptors. In line with this 
conclusion was the observation that pertussis toxin, known to inactivate Gi/o 
proteins prevented the stimulatory effect of carbachol, both in MRC-5 cells and 
primary human lung fibroblasts. Mitogen-activated protein kinase (MAP kinase) / 
extracellular signal–regulated kinase 1/2 (ERK-1/2) is one of the classical 
pathways mediating proliferative responses induced by various stimuli including 
activation of G-protein coupled receptor and  muscarinic receptors (both, M2 and 
M3) have been shown to be able to activate this pathway so we looked into this 
possibility. In our present study we demonstrated that in pulmonary human lung 
fibroblasts activation of muscarinic receptors indeed caused an increase in the 
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phosphorylated, i.e. activated form of the ERK-MAP kinase which was blocked   
by PD 98059 a specific inhibitor of the MAPK-activating enzymes (MEK) These 
observations strongly support the conclusion that muscarinic stimulation of 
proliferation in human lung fibroblasts is mediated via the classical MEK-ERK 
MAPK cascade. To illuminate further the signalling pathways, linking the 
muscarinic receptor stimulation and activation of MAPK cascade we explored 
several putative pathways that might be involved in this process and 
demonstrated the role of Raf-1 using GW5074 a specific Raf-1 inhibitor in 
activation of MAPK pathway in response to muscarinic stimulation in MRC-5 
fiobroblasts at a functional and protein level. Recently studies were carried out in 
our laboratory on pulmonary fibroblasts investigating whether muscarinic 
mechanisms were involved in collagen synthesis in turn contributing to the airway 
remodelling process. These studies confirmed that muscarinic stimulation indeed 
lead to increased collagen synthesis and activation of the MAPK cascade in a 
pertussiss toxin sensitive manner thus implicating a pivotal role for the M2 
muscarinic receptors in this process (201).    
In conclusion, human lung fibroblasts express muscarinic receptors, which 
obviously mediate proliferative stimulus via a Gi/o-Raf-1-MEK-MAPK/ERK 
pathway, an effect which might contribute to structural changes known to occur in 
chronic obstructive airway diseases. Prolonged blockade of these receptors may 
contribute to the long term beneficial effects of anticholinergics, as observed for 
example, for the long-acting muscarinic antagonist, tiotropium, in COPD. 
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